"Analysis.group","Analysis.number","Analysis.name","Subgroup","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","Bias.arising.from.the.randomization.process.judgement","Bias.arising.from.the.randomization.process.support","Bias.due.to.deviations.from.intended.interventions.judgement","Bias.due.to.deviations.from.intended.interventions.support","Bias.due.to.missing.outcome.data.judgement","Bias.due.to.missing.outcome.data.support","Bias.in.measurement.of.the.outcome.judgement","Bias.in.measurement.of.the.outcome.support","Bias.in.selection.of.the.reported.result.judgement","Bias.in.selection.of.the.reported.result.support","Overall.bias.judgement","Overall.bias.support","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Afzal 2021",2021,0,0,0,0,0,65,0,0,0,65,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>1.2 Y</p><p>An online statistical computing web program (www. Sealedenvelope.com) was utilized to randomize the assignment of the patient (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 Y</p><p>open-labeled clinical trial (page 2, paragraph 4, line 1)</p><p>2.2 Y</p><p>open-labeled clinical trial (page 2, paragraph 4, line 1)</p><p>2.3 N</p><p>No deviation was observed in each group (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>No deviation was observed in each group (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Table 3-5)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Low risk","<p>5.1</p><p>5.2 N</p><p>Outcomes included in our analyses were prespecified.</p><p>5.3 NI</p><p>The detail of statistical analysis was not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Barba-Navarro 2017",2017,0,0,0,0,4,115,0,0,4,118,0,0,7.412288,1.026087,0.262856,4.005435,NA,"Low risk","<p>1.1 Y</p><p>Page 2. ""Randomization"" paragraph says, ""Randomization was per-formed by the Epidat 3.1 program, and allocation was imple-mented by a clinical research coordinator who was not directlyinvolved with the study.""</p><p>1.2 PY</p><p>Page 2. ""Randomization"" paragraph says, ""Randomization was per-formed by the Epidat 3.1 program, and allocation was imple-mented by a clinical research coordinator who was not directlyinvolved with the study.""</p><p>1.3 PN</p><p>Page 3 ""Study participants"" paragraph, line 4 says, ""No other significant variables were foundbetween groups (Table 1). ""</p>","High risk","<p>2.1 PN</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>2.2 PN</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows that this is not an ITT analysis.</p><p>2.7 PY</p><p>15/248 was omitted. Thus the influence might not be minimal.</p>","Low risk","<p>3.1 PY</p><p>All of the Table data were based on the same participants number.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 PN</p><p>These extracted outcomes are objective.</p><p>4.3 N</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>The definition of AKI was AKIN in the protocol, NCT02417896.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Beaver 2018",2018,0,0,0,0,0,14,0,0,0,15,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed by the investigational drug services and concealed until the study was completed. (line 3, paragraph5, page 2)</p><p>1.2 Y</p><p>Random allocation sequences were generated by two-factor randomized block design stratified by gender.(line 1, paragraph 5, page 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.2 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes were pre-specified in the protocol</p><p>5.3 NI</p><p>Anayses were not desribed in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Cinotti 2021",2021,0,0,0,0,6,82,0,0,4,89,0,0,9.101092,1.628049,0.476312,5.564718,NA,"Low risk","<p>1.1 Y</p><p>The randomization scheme was performed in blocks of 6, balanced (1:1 ratio) and stratified by center, chronic treatment by diuretic or not, and episode of acute kidney injury or not, defined as extra-renal replacement therapy or a creatinine blood level ≥180 μmol L−1 (page 3, paragraph 3, line 3)</p><p>1.2 Y</p><p>The randomization sequence was generated by a stat-istician at the clinical research unit (CHU Nantes) who had no role in patient recruitment. (page 3, paragraph 3, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.2 Y</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.3 PN</p><p>This study's intevention does not seem to deviate from clinical practice.</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>As planned, analyses were performed on all randomized patients meeting the study inclusion and non-inclusion criteria (Modified Intention to Treat Population)</p><p>2.7</p>","Low risk","<p>3.1 N</p><p>1 patient may lost to follow-up in Intervention group between Day 28 and 60 (Fig. 1)</p><p>3.2 PY</p><p>The number of missing data was small enough (only 1, Fig. 1)</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 PY</p><p>This study was single-blinded (page 3, paragraph 3, line 12)</p><p>4.4 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Dussol 2006",2006,0,0,0,0,0,79,0,0,0,77,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.2 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 PN</p><p>Results of all patients were reported</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>Results of all patients were reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Results of all patients were reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1 NI</p><p>The protocol was not available</p><p>5.2 PN</p><p>The authors reported specific outcomes</p><p>5.3 NI</p><p>The number of pre-specified analyses was unclear</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Ejaz 2009",2009,0,0,0,0,2,45,0,0,3,49,0,0,4.526192,0.725926,0.127055,4.147566,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.2 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.3 N</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>Some concerns</p><p>2.1 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.2 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>This study was not classified as ITT</p><p>2.7 PN</p><p>The influence might be minimal.</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were analyzed (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams were blinded to group assignment.""</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>Predefined outcomes in the protocol were reported (line 1, paragraph 3, page 2)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Emara 2022",2022,0,0,0,0,0,39,0,0,0,41,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>a computer-generated table of random numbers with four or six permuted blocks (page 2, paragraph 6, line 3).</p><p>1.2 Y</p><p>The group allocation was concealed in sequentially numbered,<br>sealed, and opaque envelopes.(page 2, paragraph 6, line 5)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Some concerns","<p>2.1 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.3 NI</p><p>the reasons for the withdrawal of the consent were not reported</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Fakhari 2017",2017,0,0,0,0,0,41,0,0,0,41,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.2 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.2 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p><p>2.7 PN</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p>","Low risk","<p>3.1 PY</p><p>Table2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 NI</p><p>The description about the outcome assessor was not available</p><p>4.4 PN</p><p>The outcome is objective</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The protocol was preregistered in IRCT138706091127N1.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Hisatomi 2012",2012,0,0,0,0,0,44,0,0,1,44,0,0,1.364825,0.333333,0.013948,7.966233,NA,"Low risk","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","High risk","<p>2.1 Y</p><p>open-label (line1, paragraph4, page 2)</p><p>2.2 Y</p><p>open-label (line1, paragraph4, page 2)</p><p>2.3 PY</p><p>The three dropouts from the Carperitide group were for the following reasons: (1) the surgical technique was changed to off-pump coronary artery bypass (OPCAB); (2) the start of carperitide treatment was too late; and (3) the patient was switched to another clinical trial. The three dropouts from the control group were for the following reasons: (1) the surgical technique was changed to OPCAB; (2) suffi cient data could not be obtained; and (3) the patient withdrew consent. (line 6, paragraph 6, page 2)</p><p>2.4 NI</p><p>It is unclear whether the deviations can affect outcomes. But 7 patients in Control group were administered carperitide because of heart failure and water balance problems after surgery (line 17, paragraph 6, page 3). The deviation favours the Control group.</p><p>2.5 N</p><p>11 excluded patients in Control group, 1 excluded patient in Carperitide group (Fig.1)</p><p>2.6</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Nearly 95% of outcome data were obtained.(Fig.2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 Y</p><p>open-label</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol is not available</p><p>5.3 NI</p><p>The protocol is not available</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Hu 2021",2021,0,0,0,0,0,115,0,0,0,115,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.2 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.3 PN</p><p>The number of deviations in each group was small enough and almost the same.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>Not reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Only 1 in Intervention group, 2 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","MAHAL 2021",2021,0,0,0,0,4,25,0,0,3,26,0,0,7.088678,1.386667,0.344474,5.581972,NA,"Low risk","<p>1.1 Y</p><p>Block randomization was done with block size of 10. An inde-pendent statistician using computer-generated random number table performed sequence generation (in line 1, paragraph 4, page 2).</p><p>1.2 Y</p><p>Allocation concealment was done using sequentially numbered, opaque, sealed envelopes. (in line 4, paragraph4, page 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 Y</p><p>open-label study (page 2, paragraph 3, line 21)</p><p>2.2 Y</p><p>open-label study (page 2, paragraph 3, line 21)</p><p>2.3 PN</p><p>Results of all patients were reported (Fig.2)</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported (Fig.2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Fig.2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and mortality</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and mortality</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and mortality</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>All outcomes declared in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not declared in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","MYTHOS 2012",2012,0,0,0,0,1,87,0,0,3,83,0,0,2.732401,0.318008,0.03375,2.996433,NA,"Some concerns","<p>1.1 Y</p><p>The manuscript says ""Patients wererandomized, in a 1:1 ratio, toreceive either furosemide withmatched hydration (FMHgroup)or hydration with isotonic saline(control group) based on computer-generatedrandom numbers.Randomization was stratified for elective or urgent coronaryangiography.""</p><p>1.2 NI</p><p>not reported</p><p>1.3 N</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 PN</p><p>Renal guard system was not widley performed. But, in a part of the developed countries, it could be applicable.</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>A part of the results of intention to treat analysis was not reported</p><p>2.7 PN</p><p>The impact could be limited because the number of exclusion was small.</p>","Low risk","<p>3.1 PY</p><p>Some persons date were not reported. But the influence could be limited.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 PN</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Prespecified outcomes in the protocol were reported</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Mahesh 2008",2008,0,0,0,0,1,21,0,0,0,21,0,0,1.389445,3,0.129126,69.699364,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>Double blinded-trial (page 2, paragraph 4, line 1)</p><p>2.2 N</p><p>Double blinded-trial (page 2, paragraph 4, line 1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported</p><p>2.7</p>","High risk","<p>3.1 NI</p><p>It was unclear whether all patients were followed up.</p><p>3.2 PN</p><p>There was no sensitivity analysis to correct the bias</p><p>3.3 NI</p><p>not reported</p><p>3.4 NI</p><p>not reported</p><p>&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.2 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>That is unclear becaus the protocol is not available</p><p>5.3 NI</p><p>That is unclear becaus the protocol is not available</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Majumdar 2009",2009,0,0,0,0,5,46,0,0,4,46,0,0,8.803646,1.25,0.358255,4.361422,NA,"Low risk","<p>1.1 Y</p><p>Randomization was conducted by an independentbiostatistician at the Epidemiology Coordinating Centre</p><p>1.2 Y</p><p>we began to test this hypothesis in a randomized alloca-tion-concealed controlled trial with blinded ascer-tainment of outcomes (page 2, paragraph 4, line 7)</p><p>1.3 PN</p><p>The proportion of women was significantly higher in control group (Table 1).</p>","Some concerns","<p>2.1 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.2 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Only per-protocol analysis was applied</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""440895360050513138"" type=""FIGURE"">Figure 2</a>)</p>","Low risk","<p>3.1 N</p><p>5 in Intervention group and 6 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2 N</p><p>Only per-protocol analysis was applied</p><p>3.3 PN</p><p>Main cause of missing was ""Unable to contact"" and the proportion in each group was the same (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Mori 2014",2014,0,1.53492675716571,0,0,0,20,0,0,0,22,0,2.35600014986325,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 Y</p><p>""Study protocol"" section says, "" A computerised random number generator was used to perform the allocation sequence."" and ""The random allocationsequences were concealed until the study had been com-pleted. ""</p><p>1.2 Y</p><p>""Study protocol"" section says, "" A computerised random number generator was used to perform the allocation sequence."" and ""The random allocationsequences were concealed until the study had been com-pleted. ""</p><p>1.3 PY</p><p>There might be a difference of the number of patients with diabetes mellitus betwee two groups</p>","High risk","<p>2.1 N</p><p>This study is a doule-blinded one. Also, ""Study protocol"" section says, "" The allocation into the treat-ment or the placebo group and the preparation of thestudy drug were performed by the hospital pharmacy.""</p><p>2.2 N</p><p>This study is a doule-blinded one. Also, ""Study protocol"" section says, "" The allocation into the treat-ment or the placebo group and the preparation of thestudy drug were performed by the hospital pharmacy.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows this study is not an ITT.</p><p>2.7 PY</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows the proportion of the lost follow-up is more than 10%.</p>","High risk","<p>3.1 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows some patients were lost or removed.</p><p>3.2 N</p><p>There seems to be no evidence of demonstrating the unbiasness</p><p>3.3 PY</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows the proportion of the lost follow-up is more than 10%.</p><p>3.4 NI</p><p>There is no information to demonstrate or deny the influence.</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 N</p><p>These extracted outcomes are objective.</p><p>4.3 N</p><p>Study protocol section says, "" The study participants, physicians, nurses and dataanalysis teams were blinded to group assignment.""</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>The prespecified protocol described the intended outcomes (UMIN000011650).</p><p>5.3 NI</p><p>The prespecified protocol does not describe the analysis plan (UMIN000011650).</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","PROTECT-TAVI 2015",2015,0,0,0,0,0,56,0,0,0,56,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was obtained with computer-generated codes, which were sealed in sequentiallynumbered envelopes</p><p>1.2 Y</p><p>Randomization was obtained with computer-generated codes, which were sealed in sequentiallynumbered envelopes</p><p>1.3 PN</p><p>Baseline characterics on Table 1 were almost the same between two groups and all p values were higher than 0.05</p>","Low risk","<p>2.1 NI</p><p>Not mentioned</p><p>2.2 NI</p><p>Not mentioned. Considering the method to apply RenalGuard system it was impossible to conceal which intervention was applied to each patient</p><p>2.3 PN</p><p>Results from all patients were reported</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>All analyses were performed following the intention-to-treat principle</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results from all patients were reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>AKI was defined as an absolute reduction in kidneyfunction (#72 h) and defined as: 1) stage 1: increase inserum creatinine to 150% to 200% (1.5 to 2.0 in-crease compared with baseline) or increase of 0.3mg/dl ($26.4 mmol/l); 2) stage 2: increase in serumcreatinine to 200% to 300% (2.0 to 3.0 increasecompared with baseline); and 3) stage 3: increase inserum creatinine to 300% (&gt;3 increase comparedwith baseline) or serum creatinine of 4.0 mg/dl(354 mmol/l) with an acute increase of at least 0.5mg/dl (44 mmol/l)</p><p>4.2 N</p><p>AKI was defined as an absolute reduction in kidneyfunction (#72 h) and defined as: 1) stage 1: increase inserum creatinine to 150% to 200% (1.5 to 2.0 in-crease compared with baseline) or increase of 0.3mg/dl ($26.4 mmol/l); 2) stage 2: increase in serumcreatinine to 200% to 300% (2.0 to 3.0 increasecompared with baseline); and 3) stage 3: increase inserum creatinine to 300% (&gt;3 increase comparedwith baseline) or serum creatinine of 4.0 mg/dl(354 mmol/l) with an acute increase of at least 0.5mg/dl (44 mmol/l)</p><p>4.3 NI</p><p>Not mentioned</p><p>4.4 N</p><p>All outcomes were objective and they could not be influenced by assessors</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Piardi 2021",2021,0,0,0,0,1,26,0,0,0,25,0,0,1.381181,2.888889,0.123181,67.751506,NA,"Low risk","<p>1.1 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.2 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.2 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>ITT analysis seemed to be applied because denominator of the fraction in table 3 were 26 and 25 (before lost to follow-up)</p><p>2.7</p>","Low risk","<p>3.1 PN</p><p>In total, 4 patients lost to follow-up (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.2 N</p><p>No sensitivity analysis was performed</p><p>3.3 PN</p><p>All reasons for missingness were discharges (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>All outcomes that were declared in the protocol were reported</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The outcome is prespecified in the protocol.</p><p>5.3 NI</p><p>Statistical analyses were not pre-specified in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","REDUCE-AKI 2019",2019,0,0.929445783179129,0,0,0,68,0,0,3,68,0,0.863869463869464,1.585868,0.142857,0.00752,2.714014,NA,"Low risk","<p>1.1 Y</p><p>patients were randomizedin a 1:1 fashion using closed envelopes by block randomization (groups of 10) (page 2, paragraph 9, line 2)</p><p>1.2 Y</p><p>patients were randomizedin a 1:1 fashion using closed envelopes by block randomization (groups of 10) (page 2, paragraph 9, line 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind, sham-controlled study (page 2, paragraph 3, lne 2)</p><p>2.2 N</p><p>double-blind, sham-controlled study (page 2, paragraph 3, lne 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>No deviation was reported (Table 2-6) and ITT analysis seemed to be automaticlly applied</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Table 2-6</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors' protocol paper says, ""Theinterventional cardiologist conducting the TAVI procedureis also blinded to the study treatment arm. The supervisingphysician, core labs, the biostatisticians performing the ana-lysis, the members of the Clinical Event Committee (CEC),aswellasthemembersoftheDataSafetyMonitoringBoard(DSMB)areblindedtotreatmentassignmentuntilstudy completion and after the database has been unlocked""</p><p>4.4</p><p>4.5</p>","Low risk","<p>5.1 Y</p><p>The analysis was performed based on the prespecified protocol</p><p>5.2 N</p><p>The pre-registerd protocol is available and outcome to be included in our analysis were pre-specified.</p><p>5.3 N</p><p>The pre-registerd protocol is available and analyses were pre-specified.</p>","Low risk","<p>'Low risk of bias' in all domains</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","REMEDIAL III 2020",2020,0,0.649933720128417,0,0,4,355,0,0,6,353,0,0.422413840559964,8.707363,0.662911,0.188688,2.328979,NA,"Low risk","<p>1.1 Y</p><p>An independent statistician generatedthe randomization list with permuted blocks, and theblock size was not disclosed to the investigatorsenrolling the patients (Random Allocation Software1.0, Microsoft Corp., Redmond, Washington) (page 4, paragraph 1, line 2).</p><p>1.2 Y</p><p>An independent statistician generatedthe randomization list with permuted blocks, and theblock size was not disclosed to the investigatorsenrolling the patients (Random Allocation Software1.0, Microsoft Corp., Redmond, Washington) (page 4, paragraph 1, line 2).</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiatedtrial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiatedtrial (page 2, paragraph 2, line 1)</p><p>2.3 Y</p><p>2 refused Foley cathether in UFR grouip (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.5</p><p>2.6 PN</p><p>Per-protocol analysis was applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 N</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 Y</p><p>""Patient population"" section, line 1 says, ""This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiated trial (6). ""</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Low risk","<p>5.1 PY</p><p>The analysis was performed based on the prespecified protocol</p><p>5.2 PN</p><p>Outcomes were pre-specified in the protocol</p><p>5.3 PN</p><p>All pre-specified analyses in the protocol were performed</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Ridgen 1984",1984,0,0,0,0,0,20,0,0,0,20,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>There is not enough information to judge.</p><p>1.2 NI</p><p>There is not enough information to judge.</p><p>1.3 NI</p><p>There is not enough information about the backgrounds.</p>","High risk","<p>2.1 NI</p><p>There is no enough information to judge.</p><p>2.2 NI</p><p>There is no enough information to judge.</p><p>2.3 NI</p><p>There is no enough information to judge.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>There is no evidence for denying the appropriateness.</p><p>2.7 NI</p><p>There is no evidence for denying the appropriateness.</p>","High risk","<p>3.1 NI</p><p>There is no enough information to judge.</p><p>3.2 PN</p><p>There is no evidence.</p><p>3.3 NI</p><p>There is no enough information to judge.</p><p>3.4 NI</p><p>There is no enough information to judge.</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p><p>5.3 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","STRENGTH 2022",2022,0,0,0,0,1,122,0,0,2,126,0,0,2.411856,0.516393,0.047435,5.621652,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Method says, ”Patients were randomized in a 1:1 ratio via an electronic data capture.” But there is no information about the process of clarifying the randmization.</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Some concerns","<p>2.1 Y</p><p>Their protocol (NCT02793661) says that this study is an open-label.</p><p>2.2 Y</p><p>Their protocol (NCT02793661) says that this study is an open-label.</p><p>2.3 NI</p><p>There is no information to demonstrate the deviation.</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>Figure1 shows that this study a kind of mITT.</p><p>2.7</p>","High risk","<p>3.1 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows some of the pariticipants were lost.</p><p>3.2 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows 218 of 248 patients were lost.</p><p>3.3 NI</p><p>There is no information to demonstrate or deny the influence.</p><p>3.4 NI</p><p>There is no information to demonstrate or deny the influence.</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>Their protocol (NCT02793661) says that this study is an open-label. There is no information about the outcome assessor.</p><p>4.4 PN</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The prespecified outcomes seem to be available in published report and supplementary file.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Sezai 2006a",2006,0,0,0,0,0,75,0,0,1,73,0,0,1.355636,0.324561,0.013436,7.840332,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Methods section, line7 says, ""The allocation was random"". But, the actual method was not mentioned in detail.</p><p>1.3 PN</p><p>There seems not to be much difference between the two groups in Table1.</p>","Some concerns","<p>2.1 NI</p><p>Althoug blind injection was performed in each group, blindeness for whom is unclear.</p><p>2.2 NI</p><p>Althoug blind injection was performed in each group, blindeness for whom is unclear.</p><p>2.3 PN</p><p>""blind injection"" might lead to no deviations</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>The data of two patients were not reported. The reason for the lost follow-up seems unclear.</p><p>2.7 PN</p><p>The number of deviation is small.</p>","High risk","<p>3.1 NI</p><p>148 of the 150 patients completed the protocol, but it is unclear wheter all patients were followed-up.</p><p>3.2 PN</p><p>148 of the 150 patients completed the protocol, but it is unclear wheter all patients were followed-up.</p><p>3.3 NI</p><p>There dose not seem to be any analysis about the missing.</p><p>3.4 NI</p><p>There dose not seem to be any analysis about the missing.</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 N</p><p>These extracted outcomes are objective.</p><p>4.3 NI</p><p>There is no information for the judgement.</p><p>4.4 N</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p><p>5.3 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Sezai 2007",2007,0,0,0,0,0,63,0,0,2,61,0,0,1.511192,0.19375,0.009491,3.955167,NA,"Some concerns","<p>1.1 NI</p><p>Method section, line8 says, ”We randomly assigned the patients into 2 groups as follow""</p><p>1.2 NI</p><p>Method section, line8 says, ”We randomly assigned the patients into 2 groups as follow""</p><p>1.3 PN</p><p>There seems not to be much difference between the two groups in Table1.</p>","High risk","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 NI</p><p>There is no information for the judgemen about the deviation.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>There is no information for the judgement about ITT analysis or study flow.</p><p>2.7 NI</p><p>There is no information for the judgement about ITT analysis or study flow.</p>","High risk","<p>3.1 NI</p><p>There is no information of the paricipants number in each table.</p><p>3.2 PN</p><p>It is not easy to demonstrate the unbiased result.</p><p>3.3 NI</p><p>There is no information for the judgement.</p><p>3.4 NI</p><p>There is no information for the judgement.</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 N</p><p>These extracted outcomes are objective.</p><p>4.3 NI</p><p>There is no information for the outcome assesor.</p><p>4.4 N</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>There is no enough information about the preregisterd protcol.</p><p>5.2 NI</p><p>There is no enough information about the preregisterd protcol or the intended outcomes.</p><p>5.3 NI</p><p>There is no enough information about the preregisterd protcol or the intended analysis.</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Sezai 2009",2009,0,0,0,0,0,251,0,0,4,253,0,0,1.616243,0.111993,0.006061,2.069322,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>The patients were randomly allocated to 2 groups bydrawing lots: 1 group received infusion of hANP in a blinded manner (hANP group) and 1 groupreceived physiological saline in the same manner (placebogroup).</p><p>2.2 N</p><p>The patients were randomly allocated to 2 groups bydrawing lots: 1 group received infusion of hANP in a blinded manner (hANP group) and 1 groupreceived physiological saline in the same manner (placebogroup).</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcomes of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Sezai 2011a",2011,0,0,0,0,0,33,0,0,0,34,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1</p><p>1.2 NI</p><p>Study Protocol, line1</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind</p><p>2.2 N</p><p>double-blind</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>The number of exclusion was small.</p>","Low risk","<p>3.1 Y</p><p>There were only 3 deviations out of 68 subjects in the study (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PY</p><p>The primary outcome was different from the protocol.</p><p>5.3 NI</p><p>The detailed analysis plan was not mentioned in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Sezai 2011b",2011,0,0,0,0,2,141,0,0,13,144,0,0,6.358074,0.157119,0.036109,0.683676,NA,"Some concerns","<p>1.1 Y</p><p>They were randomized by the lottery method into 2 groups (page 2, paragraph 3, line 9)</p><p>1.2 NI</p><p>not reoprted</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>randomized, double-blind, placebo-controlled study (page 2, paragraph 3, line 2)</p><p>2.2 N</p><p>randomized, double-blind, placebo-controlled study (page 2, paragraph 3, line 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Per-protocol analyses was applied</p><p>2.7 PN</p><p>The number of exclusion was small.</p>","Low risk","<p>3.1 PY</p><p>None of them was lost to follow-up (page 3, pargraph 6, line 9)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data</p><p>4.2 N</p><p>The outcomes were objective including laboratory data</p><p>4.3 NI</p><p>not repoted</p><p>4.4 PN</p><p>The outcomes were objective including laboratory data</p><p>4.5</p>","High risk","<p>5.1</p><p>5.2 PY</p><p>Not all of prespecified outcomes were reported (e.g. renin activity)</p><p>5.3 NI</p><p>Detailed analysis plan was not provided in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Smith 2008",2008,0,0,0,0,0,23,0,0,0,24,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Some concerns","<p>2.1 NI</p><p>not reported</p><p>2.2 Y</p><p>Perfusionists caring for the patientin theatre were not blinded to group allocation,</p><p>2.3 PN</p><p>Only 1 in mannitol group and 2 in control group deviated from the protocol. (page 2, paragraph 5, line 2)</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>Only 1 in mannitol group and 2 in control group deviated from the protocol. (page 2, paragraph 5, line 2)</p>","Low risk","<p>3.1 PY</p><p>Nearly 95% of outcome data were obtained.(page 2, paragraph 5, line 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data</p><p>4.2 N</p><p>The outcomes were objective including laboratory data</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Svenmarker 2024",2024,0,0,0,0,0,98,0,0,0,97,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>not reported (just written as ""simple random sampling""</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Low risk","<p>2.1 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.2 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.3&nbsp;</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 Y</p><p>Only 5 were lost to follow-up (Figure 1)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.2 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Sward 2004",2004,0,0,0,0,6,29,0,0,14,30,0,0,21.017684,0.44335,0.197469,0.995391,NA,"Low risk","<p>1.1 Y</p><p>A statistician using a computerized ran-dom-number generator performed the alloca-tion sequence. (page 2, paragraph 3, line 1)</p><p>1.2 Y</p><p>Treatment was assigned using closed envelopes. (page 2, paragraph 3, line 3)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind, placebo-controlled study (page 2, pargraph 2, line 2)</p><p>2.2 N</p><p>double-blind, placebo-controlled study (page 2, pargraph 2, line 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>The impact could be limited because the number of exclusion was small</p>","Low risk","<p>3.1 PY</p><p>Outcome data for all patients are reported in Table5.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.2 N</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.3 NI</p><p>not repoted</p><p>4.4 PN</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Tholen 2023",2023,0,0,0,0,3,34,0,0,8,37,0,0,8.905006,0.408088,0.117797,1.413756,NA,"Low risk","<p>1.1 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.2 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.2 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PN</p><p>per-protocol analysis seemed to be applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes we obtained were not pre-specified (protocol)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Voigtländer‑Buschmann 2023",2023,0,0,0,0,1,47,0,0,0,51,0,0,1.362548,3.25,0.135631,77.876852,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Some concerns","<p>2.1 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.3 NI</p><p>the reasons for the withdrawal of the consent were not reported</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,2,"Any use of kidney replacement therapy","","SUBGROUP_AND_OVERALL","Witteles 2007",2007,0,0,0,0,0,39,0,0,1,36,0,0,1.368783,0.308333,0.012961,7.335004,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Randomization was performed by the research pharmacist at each site using a random number generator, but the detail is unclear.</p><p>1.3 PN</p><p>The proportion of coronary artery disease is significantly different. But the influence could not be substantial.</p>","Low risk","<p>2.1 PN</p><p>The end of Introduction section says, "" a pro-spective, randomized, double-blind, placebo-controlledclinical trial"" But, the methodology is unclear.</p><p>2.2 PN</p><p>The end of Introduction section says, "" a pro-spective, randomized, double-blind, placebo-controlledclinical trial"" But, the methodology is unclear.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>All patients enrolled in this study seemed to be analyzed.</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcome data for all patients are shown in Table 2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 PN</p><p>These extracted outcomes are objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes pre-registerd in the protocol were reported</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
1,6,"Changes in serum creatinine within 30 days (mg/dL]","","SUBGROUP_AND_OVERALL","Hager 1996",1996,0,0,1.297,0.185,0,62,1.176,0.224,0,59,0,0,15.208088,0.586695,0.222392,0.950997,NA,"Low risk","<p>1.1 Y</p><p>using random numbers table (page 3, paragraph 2, line 2)</p><p>1.2 Y</p><p>The hospital pharmacy randomly assigned furosemide and an equal volume of 5% glucose (placebo) to identical containers (page 3, paragraph 2, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>The authors says, ""121 patients after major vascular, chest and abdominal surgery were enrolled into this rendomized, double-blind, placebo^controlled study during a 6 months period.""(page3, paragraph1, line1)</p><p>2.2 N</p><p>The authors says, ""121 patients after major vascular, chest and abdominal surgery were enrolled into this rendomized, double-blind, placebo^controlled study during a 6 months period.""(page3, paragraph1, line1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Only per-protocol analysis was applied</p><p>2.7 PN</p><p>The number of patients excluded from the analyses was quite small (<a href=""440895360050513138"" type=""FIGURE"">Figure 2</a>)</p>","Low risk","<p>3.1 PY</p><p>Almost all outcomes at discharge were available (<a href=""440895360050513138"" type=""FIGURE"">Figure 2</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>the protocol was not available</p><p>5.3 NI</p><p>the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
1,6,"Changes in serum creatinine within 30 days (mg/dL]","","SUBGROUP_AND_OVERALL","Hu 2021",2021,0,0,-0.052,0.359,0,115,-0.017,0.432,0,115,0,0,16.129297,-0.087831,-0.34643,0.170768,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.2 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.3 PN</p><p>The number of deviations in each group was small enough and almost the same.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>Not reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Only 1 in Intervention group, 2 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
1,6,"Changes in serum creatinine within 30 days (mg/dL]","","SUBGROUP_AND_OVERALL","Jafari 2018",2018,0,0,-0.12,0.22,0,22,-0.005,0.2,0,21,0,0,12.59692,-0.536311,-1.145968,0.073347,NA,"Low risk","<p>1.1 NI</p><p>The maniscript says using a simple randomization procedure, but the details are not reported.</p><p>1.2 Y</p><p>The allocation sequence was concealed from the researcher enrolling and determining allocation by using sequentially numbered opaque envelopes.</p><p>1.3 PN</p><p>There seems not to be much difference between the two groups in Table1.</p>","Low risk","<p>2.1 N</p><p>single-blinded study (page 2, paragraph 5, line 1) The neurosurgeon, healthcare providers, and data collectors were aware of the patients’ allocations, but the outcome assessors and data analysts remained blinded to this.</p><p>2.2 Y</p><p>The neurosurgeon, healthcare providers, and data collectors were aware of the patients’ allocations.</p><p>2.3 PN</p><p>2 in intervention 4 in control did not receive allocated intervention (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>All subjects who took allocated intervention were included (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a></p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 N</p><p>the outcome assessors and data analysts remained blinded to this</p><p>4.4</p><p>4.5</p>","High risk","<p>5.1</p><p>5.2 PY</p><p>All outcomes in the manuscirpt was not prespecified in the protocol and some pre-specified ones were not reported (Protocol)</p><p>5.3 NI</p><p>Detailed analysis plan was not provided in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
1,6,"Changes in serum creatinine within 30 days (mg/dL]","","SUBGROUP_AND_OVERALL","Majumdar 2009",2009,0,0,0.8,1.1,0,46,0.2,0.6,0,46,0,0,14.647269,0.67154,0.250997,1.092083,NA,"Low risk","<p>1.1 Y</p><p>Randomization was conducted by an independentbiostatistician at the Epidemiology Coordinating Centre</p><p>1.2 Y</p><p>we began to test this hypothesis in a randomized alloca-tion-concealed controlled trial with blinded ascer-tainment of outcomes (page 2, paragraph 4, line 7)</p><p>1.3 PN</p><p>The proportion of women was significantly higher in control group (Table 1).</p>","Some concerns","<p>2.1 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.2 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Only per-protocol analysis was applied</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""440895360050513138"" type=""FIGURE"">Figure 2</a>)</p>","Low risk","<p>3.1 N</p><p>5 in Intervention group and 6 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2 N</p><p>Only per-protocol analysis was applied</p><p>3.3 PN</p><p>Main cause of missing was ""Unable to contact"" and the proportion in each group was the same (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
1,6,"Changes in serum creatinine within 30 days (mg/dL]","","SUBGROUP_AND_OVERALL","Piardi 2021",2021,0,0,0.5,0.37,0,26,0.27,0.4,0,25,0,0,13.126517,0.588233,0.026513,1.149953,NA,"Low risk","<p>1.1 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.2 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.2 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>ITT analysis seemed to be applied because denominator of the fraction in table 3 were 26 and 25 (before lost to follow-up)</p><p>2.7</p>","Low risk","<p>3.1 PN</p><p>In total, 4 patients lost to follow-up (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.2 N</p><p>No sensitivity analysis was performed</p><p>3.3 PN</p><p>All reasons for missingness were discharges (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>All outcomes that were declared in the protocol were reported</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The outcome is prespecified in the protocol.</p><p>5.3 NI</p><p>Statistical analyses were not pre-specified in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
1,6,"Changes in serum creatinine within 30 days (mg/dL]","","SUBGROUP_AND_OVERALL","Sands 1991",1991,0,0,-4.4,3.2,0,10,-5.1,3.7,0,10,0,0,9.778773,0.193817,-0.685264,1.072899,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reoprted</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Low risk","<p>2.1 PN</p><p>double-blinded study (line 3, paragraph 1, page 2)</p><p>2.2 PN</p><p>double-blinded study (line 3, paragraph 1, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all participants were shown in Table 2 and ITT analysis seemed to be applied.</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all participants were shown in Table 2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 N</p><p>the outcome assessors and data analysts remained blinded to this</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
1,6,"Changes in serum creatinine within 30 days (mg/dL]","","SUBGROUP_AND_OVERALL","Tholen 2023",2023,0,0,0.628,1.505,0,34,0.294,0.837,0,37,0,0,14.149499,0.274461,-0.193476,0.742398,NA,"Low risk","<p>1.1 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.2 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.2 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PN</p><p>per-protocol analysis seemed to be applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes we obtained were not pre-specified (protocol)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
1,6,"Changes in serum creatinine within 30 days (mg/dL]","","SUBGROUP_AND_OVERALL","Weinstein 1992",1992,0,0.476312329734803,0.419,0.102,0,8,0.023,0.09,0,10,0,0.226873435457395,4.363637,3.951795,2.220404,5.683186,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 NI</p><p>Baseline characteristics of each group were not reported</p>","Low risk","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 PN</p><p>Results of all patients seemed to be reported</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients seemed to be reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Results of all patients seemed to be reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome was objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcome was objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome was objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
1,14,"Subgroup analysis: acute kidney injury by definition","AKIN","SUBGROUP_AND_OVERALL","Ejaz 2009",2009,0,0.676123403782813,0,0,3,45,0,0,14,49,0,0.457142857142857,26.96659,0.233333,0.071737,0.75894,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.2 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.3 N</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.2 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>This study was not classified as ITT</p><p>2.7 PN</p><p>The influence might be minimal.</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were analyzed (<a type=""FIGURE"" href=""438659130991609896"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams were blinded to group assignment.""</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>Predefined outcomes in the protocol were reported (line 1, paragraph 3, page 2)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","AKIN","SUBGROUP_AND_OVERALL","Mori 2014",2014,0,0,0,0,6,20,0,0,16,22,0,0,73.03341,0.4125,0.20145,0.844656,NA,"Some concerns","<p>1.1 Y</p><p>""Study protocol"" section says, "" A computerised random number generator was used to perform the allocation sequence."" and ""The random allocationsequences were concealed until the study had been com-pleted. ""</p><p>1.2 Y</p><p>""Study protocol"" section says, "" A computerised random number generator was used to perform the allocation sequence."" and ""The random allocationsequences were concealed until the study had been com-pleted. ""</p><p>1.3 PY</p><p>There might be a difference of the number of patients with diabetes mellitus betwee two groups</p>","High risk","<p>2.1 N</p><p>This study is a doule-blinded one. Also, ""Study protocol"" section says, "" The allocation into the treat-ment or the placebo group and the preparation of thestudy drug were performed by the hospital pharmacy.""</p><p>2.2 N</p><p>This study is a doule-blinded one. Also, ""Study protocol"" section says, "" The allocation into the treat-ment or the placebo group and the preparation of thestudy drug were performed by the hospital pharmacy.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p><a type=""FIGURE"" href=""438659130991609896"">Figure 1</a>&nbsp;shows this study is not an ITT.</p><p>2.7 PY</p><p><a type=""FIGURE"" href=""438659130991609896"">Figure 1</a>&nbsp;shows the proportion of the lost follow-up is more than 10%.</p>","High risk","<p>3.1 N</p><p><a type=""FIGURE"" href=""438659130991609896"">Figure 1</a>&nbsp;shows some patients were lost or removed.</p><p>3.2 N</p><p>There seems to be no evidence of demonstrating the unbiasness</p><p>3.3 PY</p><p><a type=""FIGURE"" href=""438659130991609896"">Figure 1</a>&nbsp;shows the proportion of the lost follow-up is more than 10%.</p><p>3.4 NI</p><p>There is no information to demonstrate or deny the influence.</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 N</p><p>These extracted outcomes are objective.</p><p>4.3 N</p><p>Study protocol section says, "" The study participants, physicians, nurses and dataanalysis teams were blinded to group assignment.""</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>The prespecified protocol described the intended outcomes (UMIN000011650).</p><p>5.3 NI</p><p>The prespecified protocol does not describe the analysis plan (UMIN000011650).</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Afzal 2021",2021,0,0.353556005662158,0,0,29,65,0,0,28,65,0,0.12500184913978,13.758795,1.035714,0.701813,1.528475,NA,"Low risk","<p>1.1 Y</p><p>1.2 Y</p><p>An online statistical computing web program (www. Sealedenvelope.com) was utilized to randomize the assignment of the patient (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 Y</p><p>open-labeled clinical trial (page 2, paragraph 4, line 1)</p><p>2.2 Y</p><p>open-labeled clinical trial (page 2, paragraph 4, line 1)</p><p>2.3 N</p><p>No deviation was observed in each group (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>No deviation was observed in each group (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Table 3-5)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes included in our analyses were prespecified.</p><p>5.3 NI</p><p>The detail of statistical analysis was not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Barba-Navarro 2017",2017,0,0.276949710227795,0,0,50,115,0,0,34,118,0,0.0767011419952596,14.893597,1.508951,1.06129,2.14544,NA,"Low risk","<p>1.1 Y</p><p>Page 2. ""Randomization"" paragraph says, ""Randomization was per-formed by the Epidat 3.1 program, and allocation was imple-mented by a clinical research coordinator who was not directlyinvolved with the study.""</p><p>1.2 PY</p><p>Page 2. ""Randomization"" paragraph says, ""Randomization was per-formed by the Epidat 3.1 program, and allocation was imple-mented by a clinical research coordinator who was not directlyinvolved with the study.""</p><p>1.3 PN</p><p>Page 3 ""Study participants"" paragraph, line 4 says, ""No other significant variables were foundbetween groups (Table 1). ""</p>","High risk","<p>2.1 PN</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>2.2 PN</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows that this is not an ITT analysis.</p><p>2.7 PY</p><p>15/248 was omitted. Thus the influence might not be minimal.</p>","Low risk","<p>3.1 PY</p><p>All of the Table data were based on the same participants number.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 PN</p><p>These extracted outcomes are objective.</p><p>4.3 N</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>The definition of AKI was AKIN in the protocol, NCT02417896.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Beaver 2018",2018,0,0.841625411530173,0,0,8,14,0,0,12,15,0,0.708333333333333,10.370906,0.714286,0.424896,1.200774,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed by the investigational drug services and concealed until the study was completed. (line 3, paragraph5, page 2)</p><p>1.2 Y</p><p>Random allocation sequences were generated by two-factor randomized block design stratified by gender.(line 1, paragraph 5, page 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.2 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes were pre-specified in the protocol</p><p>5.3 NI</p><p>Anayses were not desribed in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Cinotti 2021",2021,0,0.724421011369484,0,0,76,82,0,0,86,89,0,0.524785801713586,23.072753,0.959161,0.892404,1.030911,NA,"Low risk","<p>1.1 Y</p><p>The randomization scheme was performed in blocks of 6, balanced (1:1 ratio) and stratified by center, chronic treatment by diuretic or not, and episode of acute kidney injury or not, defined as extra-renal replacement therapy or a creatinine blood level ≥180 μmol L−1 (page 3, paragraph 3, line 3)</p><p>1.2 Y</p><p>The randomization sequence was generated by a stat-istician at the clinical research unit (CHU Nantes) who had no role in patient recruitment. (page 3, paragraph 3, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.2 Y</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.3 PN</p><p>This study's intevention does not seem to deviate from clinical practice.</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>As planned, analyses were performed on all randomized patients meeting the study inclusion and non-inclusion criteria (Modified Intention to Treat Population)</p><p>2.7</p>","Low risk","<p>3.1 N</p><p>1 patient may lost to follow-up in Intervention group between Day 28 and 60 (Fig. 1)</p><p>3.2 PY</p><p>The number of missing data was small enough (only 1, Fig. 1)</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 PY</p><p>This study was single-blinded (page 3, paragraph 3, line 12)</p><p>4.4 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Dussol 2006",2006,0,0.601628902733777,0,0,12,79,0,0,4,77,0,0.361957336604648,3.579026,2.924051,0.985885,8.67248,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.2 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 PN</p><p>Results of all patients were reported</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>Results of all patients were reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Results of all patients were reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>The authors reported specific outcomes</p><p>5.3 NI</p><p>The number of pre-specified analyses was unclear</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Hu 2021",2021,0,0.40961098009599,0,0,10,115,0,0,21,115,0,0.167781155015197,7.010047,0.47619,0.234751,0.96595,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.2 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.3 PN</p><p>The number of deviations in each group was small enough and almost the same.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>Not reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Only 1 in Intervention group, 2 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Jafari 2018",2018,0,1.16466414773995,0,0,1,22,0,0,4,21,0,1.35644257703081,1.070848,0.238636,0.028985,1.964687,NA,"Low risk","<p>1.1 NI</p><p>The maniscript says using a simple randomization procedure, but the details are not reported.</p><p>1.2 Y</p><p>The allocation sequence was concealed from the researcher enrolling and determining allocation by using sequentially numbered opaque envelopes.</p><p>1.3 PN</p><p>There seems not to be much difference between the two groups in Table1.</p>","Low risk","<p>2.1 N</p><p>single-blinded study (page 2, paragraph 5, line 1) The neurosurgeon, healthcare providers, and data collectors were aware of the patients’ allocations, but the outcome assessors and data analysts remained blinded to this.</p><p>2.2 Y</p><p>The neurosurgeon, healthcare providers, and data collectors were aware of the patients’ allocations.</p><p>2.3 PN</p><p>2 in intervention 4 in control did not receive allocated intervention (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>All subjects who took allocated intervention were included (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a></p><p>3.2</p><p>3.3</p><p>3.4</p>","High risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 N</p><p>the outcome assessors and data analysts remained blinded to this</p><p>4.4</p><p>4.5</p>","High risk","<p>5.1</p><p>5.2 PY</p><p>All outcomes in the manuscirpt was not prespecified in the protocol and some pre-specified ones were not reported (Protocol)</p><p>5.3 NI</p><p>Detailed analysis plan was not provided in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Moriyama 2017",2017,0,0.850430669268414,0,0,2,24,0,0,9,24,0,0.723232323232323,2.227124,0.222222,0.053506,0.922935,NA,"Some concerns","<p>1.1 Y</p><p>using a computer-based stratified randomization method (line 7, paragraph 5, page 2)</p><p>1.2 NI</p><p>Any description about concealment was provided.</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 Y</p><p>this study was not blinded (line 6, paragraph 4, page 6)</p><p>2.2 Y</p><p>this study was not blinded (line 6, paragraph 4, page 6)</p><p>2.3 N</p><p>No deviation was observed (Table 2)</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcomes of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes predefined in the protocol were reported</p><p>5.3 NI</p><p>Detailed analysis plan was not provided in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Svenmarker 2024",2024,0,0,0,0,5,98,0,0,6,97,0,0,3.235749,0.82483,0.260352,2.613167,NA,"Some concerns","<p>1.1 NI</p><p>not reported (just written as ""simple random sampling""</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Low risk","<p>2.1 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.2 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.3&nbsp;</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 Y</p><p>Only 5 were lost to follow-up (Figure 1)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.2 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Tholen 2023",2023,0,0.503897562916069,0,0,21,34,0,0,26,37,0,0.253912753912754,15.351656,0.878959,0.627219,1.231738,NA,"Low risk","<p>1.1 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.2 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.2 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PN</p><p>per-protocol analysis seemed to be applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes we obtained were not pre-specified (protocol)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","KDIGO","SUBGROUP_AND_OVERALL","Voigtländer‑Buschmann 2023",2023,0,0,0,0,10,47,0,0,8,51,0,0,5.429499,1.356383,0.584983,3.145008,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Some concerns","<p>2.1 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.3 NI</p><p>the reasons for the withdrawal of the consent were not reported</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,14,"Subgroup analysis: acute kidney injury by definition","RIFLE","SUBGROUP_AND_OVERALL","Pakfetrat 2008",2008,0,1.44347165938113,0,0,5,94,0,0,16,96,0,2.08361043143652,100,0.319149,0.121825,0.836082,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Although using undisclosed codes, the way of generating codes was not reported.</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Some concerns","<p>2.1 N</p><p>Both the physician and patients were unaware of the nature of the therapy,which was carried out using undisclosed codes and　recorded by a nurse unaware of the codes.</p><p>2.2 N</p><p>Both the physician and patients were unaware of the nature of the therapy,which was carried out using undisclosed codes and　recorded by a nurse unaware of the codes.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>From the AZ group two patients did not appear atfollow-up and were excluded from the study.</p><p>2.7 PN</p><p>The impact could be limited because the number of exclusion was small.</p>","Low risk","<p>3.1 Y</p><p>Almost all patients in AZ group and NLS group were followed up (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not repoted</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","14::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.528658483913378,-0.0682003151672229,-1.04250407583191,-0.0148128919948455,-0.139949487612651,0.00354885727820543,FALSE,FALSE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Afzal 2021",2021,0,0,0,0,0,65,0,0,0,65,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>1.2 Y</p><p>An online statistical computing web program (www. Sealedenvelope.com) was utilized to randomize the assignment of the patient (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 Y</p><p>open-labeled clinical trial (page 2, paragraph 4, line 1)</p><p>2.2 Y</p><p>open-labeled clinical trial (page 2, paragraph 4, line 1)</p><p>2.3 N</p><p>No deviation was observed in each group (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>No deviation was observed in each group (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Table 3-5)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Low risk","<p>5.1</p><p>5.2 N</p><p>Outcomes included in our analyses were prespecified.</p><p>5.3 NI</p><p>The detail of statistical analysis was not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Beaver 2018",2018,0,0,0,0,0,14,0,0,0,15,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed by the investigational drug services and concealed until the study was completed. (line 3, paragraph5, page 2)</p><p>1.2 Y</p><p>Random allocation sequences were generated by two-factor randomized block design stratified by gender.(line 1, paragraph 5, page 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.2 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes were pre-specified in the protocol</p><p>5.3 NI</p><p>Anayses were not desribed in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Cinotti 2021",2021,0,0,0,0,6,82,0,0,4,89,0,0,11.638719,1.628049,0.476312,5.564718,NA,"Low risk","<p>1.1 Y</p><p>The randomization scheme was performed in blocks of 6, balanced (1:1 ratio) and stratified by center, chronic treatment by diuretic or not, and episode of acute kidney injury or not, defined as extra-renal replacement therapy or a creatinine blood level ≥180 μmol L−1 (page 3, paragraph 3, line 3)</p><p>1.2 Y</p><p>The randomization sequence was generated by a stat-istician at the clinical research unit (CHU Nantes) who had no role in patient recruitment. (page 3, paragraph 3, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.2 Y</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.3 PN</p><p>This study's intevention does not seem to deviate from clinical practice.</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>As planned, analyses were performed on all randomized patients meeting the study inclusion and non-inclusion criteria (Modified Intention to Treat Population)</p><p>2.7</p>","Low risk","<p>3.1 N</p><p>1 patient may lost to follow-up in Intervention group between Day 28 and 60 (Fig. 1)</p><p>3.2 PY</p><p>The number of missing data was small enough (only 1, Fig. 1)</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 PY</p><p>This study was single-blinded (page 3, paragraph 3, line 12)</p><p>4.4 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Dussol 2006",2006,0,0,0,0,0,79,0,0,0,77,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.2 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 PN</p><p>Results of all patients were reported</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>Results of all patients were reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Results of all patients were reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1 NI</p><p>The protocol was not available</p><p>5.2 PN</p><p>The authors reported specific outcomes</p><p>5.3 NI</p><p>The number of pre-specified analyses was unclear</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Ejaz 2009",2009,0,0,0,0,2,45,0,0,3,49,0,0,5.788215,0.725926,0.127055,4.147566,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.2 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.3 N</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>Some concerns</p><p>2.1 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.2 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>This study was not classified as ITT</p><p>2.7 PN</p><p>The influence might be minimal.</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were analyzed (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams were blinded to group assignment.""</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>Predefined outcomes in the protocol were reported (line 1, paragraph 3, page 2)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Emara 2022",2022,0,1.434034042164,0,0,0,39,0,0,0,41,0,2.05645363408521,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>a computer-generated table of random numbers with four or six permuted blocks (page 2, paragraph 6, line 3).</p><p>1.2 Y</p><p>The group allocation was concealed in sequentially numbered,<br>sealed, and opaque envelopes.(page 2, paragraph 6, line 5)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Some concerns","<p>2.1 N</p><p>This is a triple-blinded randomized controlled study (page 6, paragrph 5, line 1)</p><p>2.2 N</p><p>This is a triple-blinded randomized controlled study (page 6, paragrph 5, line 1)</p><p>2.3&nbsp;</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PN</p><p>modified ITT was applied (Table 1)</p><p>2.7 PN</p><p>≤ 5% were lost to follow-up</p>","Low risk","<p>3.1 Y</p><p>Results of almost all patients were reported (Table 3)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 N</p><p>The outcome is objective.</p><p>4.4&nbsp;</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 N</p><p>Prespecified outcomes in the protocol were reported</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Fakhari 2017",2017,0,0,0,0,0,41,0,0,0,41,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.2 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.2 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p><p>2.7 PN</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p>","Low risk","<p>3.1 PY</p><p>Table2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 NI</p><p>The description about the outcome assessor was not available</p><p>4.4 PN</p><p>The outcome is objective</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The protocol was preregistered in IRCT138706091127N1.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Hu 2021",2021,0,0,0,0,0,115,0,0,0,115,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.2 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.3 PN</p><p>The number of deviations in each group was small enough and almost the same.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>Not reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Only 1 in Intervention group, 2 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","MAHAL 2021",2021,0,0,0,0,4,25,0,0,3,26,0,0,9.065189,1.386667,0.344474,5.581972,NA,"Low risk","<p>1.1 Y</p><p>Block randomization was done with block size of 10. An inde-pendent statistician using computer-generated random number table performed sequence generation (in line 1, paragraph 4, page 2).</p><p>1.2 Y</p><p>Allocation concealment was done using sequentially numbered, opaque, sealed envelopes. (in line 4, paragraph4, page 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 Y</p><p>open-label study (page 2, paragraph 3, line 21)</p><p>2.2 Y</p><p>open-label study (page 2, paragraph 3, line 21)</p><p>2.3 PN</p><p>Results of all patients were reported (Fig.2)</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported (Fig.2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Fig.2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and mortality</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and mortality</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and mortality</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>All outcomes declared in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not declared in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","MYTHOS 2012",2012,0,0,0,0,1,87,0,0,3,83,0,0,3.494267,0.318008,0.03375,2.996433,NA,"Some concerns","<p>1.1 Y</p><p>The manuscript says ""Patients wererandomized, in a 1:1 ratio, toreceive either furosemide withmatched hydration (FMHgroup)or hydration with isotonic saline(control group) based on computer-generatedrandom numbers.Randomization was stratified for elective or urgent coronaryangiography.""</p><p>1.2 NI</p><p>not reported</p><p>1.3 N</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 PN</p><p>Renal guard system was not widley performed. But, in a part of the developed countries, it could be applicable.</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>A part of the results of intention to treat analysis was not reported</p><p>2.7 PN</p><p>The impact could be limited because the number of exclusion was small.</p>","Low risk","<p>3.1 PY</p><p>Some persons date were not reported. But the influence could be limited.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 PN</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Prespecified outcomes in the protocol were reported</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Majumdar 2009",2009,0,0,0,0,5,46,0,0,4,46,0,0,11.258336,1.25,0.358255,4.361422,NA,"Low risk","<p>1.1 Y</p><p>Randomization was conducted by an independentbiostatistician at the Epidemiology Coordinating Centre</p><p>1.2 Y</p><p>we began to test this hypothesis in a randomized alloca-tion-concealed controlled trial with blinded ascer-tainment of outcomes (page 2, paragraph 4, line 7)</p><p>1.3 PN</p><p>The proportion of women was significantly higher in control group (Table 1).</p>","Some concerns","<p>2.1 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.2 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Only per-protocol analysis was applied</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""440895360050513138"" type=""FIGURE"">Figure 2</a>)</p>","Low risk","<p>3.1 N</p><p>5 in Intervention group and 6 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2 N</p><p>Only per-protocol analysis was applied</p><p>3.3 PN</p><p>Main cause of missing was ""Unable to contact"" and the proportion in each group was the same (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","PROTECT-TAVI 2015",2015,0,0,0,0,0,56,0,0,0,56,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was obtained with computer-generated codes, which were sealed in sequentiallynumbered envelopes</p><p>1.2 Y</p><p>Randomization was obtained with computer-generated codes, which were sealed in sequentiallynumbered envelopes</p><p>1.3 PN</p><p>Baseline characterics on Table 1 were almost the same between two groups and all p values were higher than 0.05</p>","Low risk","<p>2.1 NI</p><p>Not mentioned</p><p>2.2 NI</p><p>Not mentioned. Considering the method to apply RenalGuard system it was impossible to conceal which intervention was applied to each patient</p><p>2.3 PN</p><p>Results from all patients were reported</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>All analyses were performed following the intention-to-treat principle</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results from all patients were reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>AKI was defined as an absolute reduction in kidneyfunction (#72 h) and defined as: 1) stage 1: increase inserum creatinine to 150% to 200% (1.5 to 2.0 in-crease compared with baseline) or increase of 0.3mg/dl ($26.4 mmol/l); 2) stage 2: increase in serumcreatinine to 200% to 300% (2.0 to 3.0 increasecompared with baseline); and 3) stage 3: increase inserum creatinine to 300% (&gt;3 increase comparedwith baseline) or serum creatinine of 4.0 mg/dl(354 mmol/l) with an acute increase of at least 0.5mg/dl (44 mmol/l)</p><p>4.2 N</p><p>AKI was defined as an absolute reduction in kidneyfunction (#72 h) and defined as: 1) stage 1: increase inserum creatinine to 150% to 200% (1.5 to 2.0 in-crease compared with baseline) or increase of 0.3mg/dl ($26.4 mmol/l); 2) stage 2: increase in serumcreatinine to 200% to 300% (2.0 to 3.0 increasecompared with baseline); and 3) stage 3: increase inserum creatinine to 300% (&gt;3 increase comparedwith baseline) or serum creatinine of 4.0 mg/dl(354 mmol/l) with an acute increase of at least 0.5mg/dl (44 mmol/l)</p><p>4.3 NI</p><p>Not mentioned</p><p>4.4 N</p><p>All outcomes were objective and they could not be influenced by assessors</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Piardi 2021",2021,0,0,0,0,1,26,0,0,0,25,0,0,1.766292,2.888889,0.123181,67.751506,NA,"Low risk","<p>1.1 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.2 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.2 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>ITT analysis seemed to be applied because denominator of the fraction in table 3 were 26 and 25 (before lost to follow-up)</p><p>2.7</p>","Low risk","<p>3.1 PN</p><p>In total, 4 patients lost to follow-up (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.2 N</p><p>No sensitivity analysis was performed</p><p>3.3 PN</p><p>All reasons for missingness were discharges (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>All outcomes that were declared in the protocol were reported</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The outcome is prespecified in the protocol.</p><p>5.3 NI</p><p>Statistical analyses were not pre-specified in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","REDUCE-AKI 2019",2019,0,0.929445783179129,0,0,0,68,0,0,3,68,0,0.863869463869464,2.02805,0.142857,0.00752,2.714014,NA,"Low risk","<p>1.1 Y</p><p>patients were randomizedin a 1:1 fashion using closed envelopes by block randomization (groups of 10) (page 2, paragraph 9, line 2)</p><p>1.2 Y</p><p>patients were randomizedin a 1:1 fashion using closed envelopes by block randomization (groups of 10) (page 2, paragraph 9, line 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind, sham-controlled study (page 2, paragraph 3, lne 2)</p><p>2.2 N</p><p>double-blind, sham-controlled study (page 2, paragraph 3, lne 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>No deviation was reported (Table 2-6) and ITT analysis seemed to be automaticlly applied</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Table 2-6</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors' protocol paper says, ""Theinterventional cardiologist conducting the TAVI procedureis also blinded to the study treatment arm. The supervisingphysician, core labs, the biostatisticians performing the ana-lysis, the members of the Clinical Event Committee (CEC),aswellasthemembersoftheDataSafetyMonitoringBoard(DSMB)areblindedtotreatmentassignmentuntilstudy completion and after the database has been unlocked""</p><p>4.4</p><p>4.5</p>","Low risk","<p>5.1 Y</p><p>The analysis was performed based on the prespecified protocol</p><p>5.2 N</p><p>The pre-registerd protocol is available and outcome to be included in our analysis were pre-specified.</p><p>5.3 N</p><p>The pre-registerd protocol is available and analyses were pre-specified.</p>","Low risk","<p>'Low risk of bias' in all domains</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","REMEDIAL III 2020",2020,0,0.649933720128417,0,0,4,355,0,0,6,353,0,0.422413840559964,11.135207,0.662911,0.188688,2.328979,NA,"Low risk","<p>1.1 Y</p><p>An independent statistician generatedthe randomization list with permuted blocks, and theblock size was not disclosed to the investigatorsenrolling the patients (Random Allocation Software1.0, Microsoft Corp., Redmond, Washington) (page 4, paragraph 1, line 2).</p><p>1.2 Y</p><p>An independent statistician generatedthe randomization list with permuted blocks, and theblock size was not disclosed to the investigatorsenrolling the patients (Random Allocation Software1.0, Microsoft Corp., Redmond, Washington) (page 4, paragraph 1, line 2).</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiatedtrial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiatedtrial (page 2, paragraph 2, line 1)</p><p>2.3 Y</p><p>2 refused Foley cathether in UFR grouip (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.5</p><p>2.6 PN</p><p>Per-protocol analysis was applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 N</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 Y</p><p>""Patient population"" section, line 1 says, ""This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiated trial (6). ""</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Low risk","<p>5.1 PY</p><p>The analysis was performed based on the prespecified protocol</p><p>5.2 PN</p><p>Outcomes were pre-specified in the protocol</p><p>5.3 PN</p><p>All pre-specified analyses in the protocol were performed</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Sezai 2009",2009,0,0,0,0,0,251,0,0,4,253,0,0,2.066894,0.111993,0.006061,2.069322,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>The patients were randomly allocated to 2 groups bydrawing lots: 1 group received infusion of hANP in a blinded manner (hANP group) and 1 groupreceived physiological saline in the same manner (placebogroup).</p><p>2.2 N</p><p>The patients were randomly allocated to 2 groups bydrawing lots: 1 group received infusion of hANP in a blinded manner (hANP group) and 1 groupreceived physiological saline in the same manner (placebogroup).</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcomes of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Sezai 2011a",2011,0,0,0,0,0,33,0,0,0,34,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1</p><p>1.2 NI</p><p>Study Protocol, line1</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind</p><p>2.2 N</p><p>double-blind</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>The number of exclusion was small.</p>","Low risk","<p>3.1 Y</p><p>There were only 3 deviations out of 68 subjects in the study (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PY</p><p>The primary outcome was different from the protocol.</p><p>5.3 NI</p><p>The detailed analysis plan was not mentioned in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Smith 2008",2008,0,0,0,0,0,23,0,0,0,24,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Some concerns","<p>2.1 NI</p><p>not reported</p><p>2.2 Y</p><p>Perfusionists caring for the patientin theatre were not blinded to group allocation,</p><p>2.3 PN</p><p>Only 1 in mannitol group and 2 in control group deviated from the protocol. (page 2, paragraph 5, line 2)</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>Only 1 in mannitol group and 2 in control group deviated from the protocol. (page 2, paragraph 5, line 2)</p>","Low risk","<p>3.1 PY</p><p>Nearly 95% of outcome data were obtained.(page 2, paragraph 5, line 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data</p><p>4.2 N</p><p>The outcomes were objective including laboratory data</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Svenmarker 2024",2024,0,1.46066459603582,0,0,0,98,0,0,0,97,0,2.13354106211249,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>not reported (just written as ""simple random sampling""</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Low risk","<p>2.1 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.2 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.3&nbsp;</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 Y</p><p>Only 5 were lost to follow-up (Figure 1)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.2 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Sward 2004",2004,0,0,0,0,6,29,0,0,14,30,0,0,26.877974,0.44335,0.197469,0.995391,NA,"Low risk","<p>1.1 Y</p><p>A statistician using a computerized ran-dom-number generator performed the alloca-tion sequence. (page 2, paragraph 3, line 1)</p><p>1.2 Y</p><p>Treatment was assigned using closed envelopes. (page 2, paragraph 3, line 3)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind, placebo-controlled study (page 2, pargraph 2, line 2)</p><p>2.2 N</p><p>double-blind, placebo-controlled study (page 2, pargraph 2, line 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>The impact could be limited because the number of exclusion was small</p>","Low risk","<p>3.1 PY</p><p>Outcome data for all patients are reported in Table5.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.2 N</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.3 NI</p><p>not repoted</p><p>4.4 PN</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Tholen 2023",2023,0,0,0,0,3,34,0,0,8,37,0,0,11.387959,0.408088,0.117797,1.413756,NA,"Low risk","<p>1.1 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.2 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.2 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PN</p><p>per-protocol analysis seemed to be applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes we obtained were not pre-specified (protocol)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Voigtländer‑Buschmann 2023",2023,0,1.6206796611615,0,0,1,47,0,0,0,51,0,2.62660256410256,1.742463,3.25,0.135631,77.876852,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Some concerns","<p>2.1 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.3 NI</p><p>the reasons for the withdrawal of the consent were not reported</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,17,"Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)","","SUBGROUP_AND_OVERALL","Witteles 2007",2007,0,0,0,0,0,39,0,0,1,36,0,0,1.750436,0.308333,0.012961,7.335004,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Randomization was performed by the research pharmacist at each site using a random number generator, but the detail is unclear.</p><p>1.3 PN</p><p>The proportion of coronary artery disease is significantly different. But the influence could not be substantial.</p>","Low risk","<p>2.1 PN</p><p>The end of Introduction section says, "" a pro-spective, randomized, double-blind, placebo-controlledclinical trial"" But, the methodology is unclear.</p><p>2.2 PN</p><p>The end of Introduction section says, "" a pro-spective, randomized, double-blind, placebo-controlledclinical trial"" But, the methodology is unclear.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>All patients enrolled in this study seemed to be analyzed.</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcome data for all patients are shown in Table 2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 PN</p><p>These extracted outcomes are objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes pre-registerd in the protocol were reported</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","17::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.359757201186382,-0.0108513044423716,-0.806374283536275,0.0868598811635107,-0.0212636581599446,-0.000438950724798583,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Barba-Navarro 2017",2017,0,0,0,0,4,115,0,0,4,118,0,0,14.095701,1.026087,0.262856,4.005435,NA,"Low risk","<p>1.1 Y</p><p>Page 2. ""Randomization"" paragraph says, ""Randomization was per-formed by the Epidat 3.1 program, and allocation was imple-mented by a clinical research coordinator who was not directlyinvolved with the study.""</p><p>1.2 PY</p><p>Page 2. ""Randomization"" paragraph says, ""Randomization was per-formed by the Epidat 3.1 program, and allocation was imple-mented by a clinical research coordinator who was not directlyinvolved with the study.""</p><p>1.3 PN</p><p>Page 3 ""Study participants"" paragraph, line 4 says, ""No other significant variables were foundbetween groups (Table 1). ""</p>","High risk","<p>2.1 PN</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>2.2 PN</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows that this is not an ITT analysis.</p><p>2.7 PY</p><p>15/248 was omitted. Thus the influence might not be minimal.</p>","Low risk","<p>3.1 PY</p><p>All of the Table data were based on the same participants number.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 PN</p><p>These extracted outcomes are objective.</p><p>4.3 N</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>The definition of AKI was AKIN in the protocol, NCT02417896.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Beaver 2018",2018,0,0,0,0,0,14,0,0,0,15,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed by the investigational drug services and concealed until the study was completed. (line 3, paragraph5, page 2)</p><p>1.2 Y</p><p>Random allocation sequences were generated by two-factor randomized block design stratified by gender.(line 1, paragraph 5, page 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.2 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes were pre-specified in the protocol</p><p>5.3 NI</p><p>Anayses were not desribed in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Ejaz 2009",2009,0,0,0,0,2,45,0,0,3,49,0,0,8.607309,0.725926,0.127055,4.147566,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.2 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.3 N</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>Some concerns</p><p>2.1 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.2 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>This study was not classified as ITT</p><p>2.7 PN</p><p>The influence might be minimal.</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were analyzed (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams were blinded to group assignment.""</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>Predefined outcomes in the protocol were reported (line 1, paragraph 3, page 2)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Emara 2022",2022,0,0,0,0,0,39,0,0,0,41,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>a computer-generated table of random numbers with four or six permuted blocks (page 2, paragraph 6, line 3).</p><p>1.2 Y</p><p>The group allocation was concealed in sequentially numbered,<br>sealed, and opaque envelopes.(page 2, paragraph 6, line 5)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Some concerns","<p>2.1 N</p><p>This is a triple-blinded randomized controlled study (page 6, paragrph 5, line 1)</p><p>2.2 N</p><p>This is a triple-blinded randomized controlled study (page 6, paragrph 5, line 1)</p><p>2.3&nbsp;</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PN</p><p>modified ITT was applied (Table 1)</p><p>2.7 PN</p><p>≤ 5% were lost to follow-up</p>","Low risk","<p>3.1 Y</p><p>Results of almost all patients were reported (Table 3)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 N</p><p>The outcome is objective.</p><p>4.4&nbsp;</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 N</p><p>Prespecified outcomes in the protocol were reported</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Fakhari 2017",2017,0,1.64734682382186,0,0,0,41,0,0,0,41,0,2.71375155795596,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.2 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.2 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p><p>2.7 PN</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p>","Low risk","<p>3.1 PY</p><p>Table2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 NI</p><p>The description about the outcome assessor was not available</p><p>4.4 PN</p><p>The outcome is objective</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The protocol was preregistered in IRCT138706091127N1.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol (The ""statistical analysis"" section was empty)</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Mori 2014",2014,0,1.53492675716571,0,0,0,20,0,0,0,22,0,2.35600014986325,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 Y</p><p>""Study protocol"" section says, "" A computerised random number generator was used to perform the allocation sequence."" and ""The random allocationsequences were concealed until the study had been com-pleted. ""</p><p>1.2 Y</p><p>""Study protocol"" section says, "" A computerised random number generator was used to perform the allocation sequence."" and ""The random allocationsequences were concealed until the study had been com-pleted. ""</p><p>1.3 PY</p><p>There might be a difference of the number of patients with diabetes mellitus betwee two groups</p>","High risk","<p>2.1 N</p><p>This study is a doule-blinded one. Also, ""Study protocol"" section says, "" The allocation into the treat-ment or the placebo group and the preparation of thestudy drug were performed by the hospital pharmacy.""</p><p>2.2 N</p><p>This study is a doule-blinded one. Also, ""Study protocol"" section says, "" The allocation into the treat-ment or the placebo group and the preparation of thestudy drug were performed by the hospital pharmacy.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows this study is not an ITT.</p><p>2.7 PY</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows the proportion of the lost follow-up is more than 10%.</p>","High risk","<p>3.1 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows some patients were lost or removed.</p><p>3.2 N</p><p>There seems to be no evidence of demonstrating the unbiasness</p><p>3.3 PY</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows the proportion of the lost follow-up is more than 10%.</p><p>3.4 NI</p><p>There is no information to demonstrate or deny the influence.</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 N</p><p>These extracted outcomes are objective.</p><p>4.3 N</p><p>Study protocol section says, "" The study participants, physicians, nurses and dataanalysis teams were blinded to group assignment.""</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>The prespecified protocol described the intended outcomes (UMIN000011650).</p><p>5.3 NI</p><p>The prespecified protocol does not describe the analysis plan (UMIN000011650).</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Piardi 2021",2021,0,0,0,0,1,26,0,0,0,25,0,0,2.626547,2.888889,0.123181,67.751506,NA,"Low risk","<p>1.1 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.2 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.2 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>ITT analysis seemed to be applied because denominator of the fraction in table 3 were 26 and 25 (before lost to follow-up)</p><p>2.7</p>","Low risk","<p>3.1 PN</p><p>In total, 4 patients lost to follow-up (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.2 N</p><p>No sensitivity analysis was performed</p><p>3.3 PN</p><p>All reasons for missingness were discharges (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>All outcomes that were declared in the protocol were reported</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The outcome is prespecified in the protocol.</p><p>5.3 NI</p><p>Statistical analyses were not pre-specified in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Ridgen 1984",1984,0,0,0,0,0,20,0,0,0,20,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>There is not enough information to judge.</p><p>1.2 NI</p><p>There is not enough information to judge.</p><p>1.3 NI</p><p>There is not enough information about the backgrounds.</p>","High risk","<p>2.1 NI</p><p>There is no enough information to judge.</p><p>2.2 NI</p><p>There is no enough information to judge.</p><p>2.3 NI</p><p>There is no enough information to judge.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>There is no evidence for denying the appropriateness.</p><p>2.7 NI</p><p>There is no evidence for denying the appropriateness.</p>","High risk","<p>3.1 NI</p><p>There is no enough information to judge.</p><p>3.2 PN</p><p>There is no evidence.</p><p>3.3 NI</p><p>There is no enough information to judge.</p><p>3.4 NI</p><p>There is no enough information to judge.</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p><p>5.3 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Sezai 2009",2009,0,0,0,0,0,251,0,0,4,253,0,0,3.073555,0.111993,0.006061,2.069322,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>The patients were randomly allocated to 2 groups bydrawing lots: 1 group received infusion of hANP in a blinded manner (hANP group) and 1 groupreceived physiological saline in the same manner (placebogroup).</p><p>2.2 N</p><p>The patients were randomly allocated to 2 groups bydrawing lots: 1 group received infusion of hANP in a blinded manner (hANP group) and 1 groupreceived physiological saline in the same manner (placebogroup).</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcomes of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Sezai 2011a",2011,0,0,0,0,0,33,0,0,0,34,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1</p><p>1.2 NI</p><p>Study Protocol, line1</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind</p><p>2.2 N</p><p>double-blind</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>The number of exclusion was small.</p>","Low risk","<p>3.1 Y</p><p>There were only 3 deviations out of 68 subjects in the study (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PY</p><p>The primary outcome was different from the protocol.</p><p>5.3 NI</p><p>The detailed analysis plan was not mentioned in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Sezai 2011b",2011,0,0,0,0,2,141,0,0,13,144,0,0,12.090937,0.157119,0.036109,0.683676,NA,"Some concerns","<p>1.1 Y</p><p>They were randomized by the lottery method into 2 groups (page 2, paragraph 3, line 9)</p><p>1.2 NI</p><p>not reoprted</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>randomized, double-blind, placebo-controlled study (page 2, paragraph 3, line 2)</p><p>2.2 N</p><p>randomized, double-blind, placebo-controlled study (page 2, paragraph 3, line 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Per-protocol analyses was applied</p><p>2.7 PN</p><p>The number of exclusion was small.</p>","Low risk","<p>3.1 PY</p><p>None of them was lost to follow-up (page 3, pargraph 6, line 9)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data</p><p>4.2 N</p><p>The outcomes were objective including laboratory data</p><p>4.3 NI</p><p>not repoted</p><p>4.4 PN</p><p>The outcomes were objective including laboratory data</p><p>4.5</p>","High risk","<p>5.1</p><p>5.2 PY</p><p>Not all of prespecified outcomes were reported (e.g. renin activity)</p><p>5.3 NI</p><p>Detailed analysis plan was not provided in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Svenmarker 2024",2024,0,0,0,0,0,98,0,0,0,97,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>not reported (just written as ""simple random sampling""</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Low risk","<p>2.1 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.2 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.3&nbsp;</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 Y</p><p>Only 5 were lost to follow-up (Figure 1)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.2 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Sward 2004",2004,0,0,0,0,6,29,0,0,14,30,0,0,39.96863,0.44335,0.197469,0.995391,NA,"Low risk","<p>1.1 Y</p><p>A statistician using a computerized ran-dom-number generator performed the alloca-tion sequence. (page 2, paragraph 3, line 1)</p><p>1.2 Y</p><p>Treatment was assigned using closed envelopes. (page 2, paragraph 3, line 3)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind, placebo-controlled study (page 2, pargraph 2, line 2)</p><p>2.2 N</p><p>double-blind, placebo-controlled study (page 2, pargraph 2, line 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>The impact could be limited because the number of exclusion was small</p>","Low risk","<p>3.1 PY</p><p>Outcome data for all patients are reported in Table5.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.2 N</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.3 NI</p><p>not repoted</p><p>4.4 PN</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Tholen 2023",2023,0,0,0,0,3,34,0,0,8,37,0,0,16.934353,0.408088,0.117797,1.413756,NA,"Low risk","<p>1.1 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.2 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.2 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PN</p><p>per-protocol analysis seemed to be applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes we obtained were not pre-specified (protocol)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,18,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Witteles 2007",2007,0,0,0,0,0,39,0,0,1,36,0,0,2.602968,0.308333,0.012961,7.335004,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Randomization was performed by the research pharmacist at each site using a random number generator, but the detail is unclear.</p><p>1.3 PN</p><p>The proportion of coronary artery disease is significantly different. But the influence could not be substantial.</p>","Low risk","<p>2.1 PN</p><p>The end of Introduction section says, "" a pro-spective, randomized, double-blind, placebo-controlledclinical trial"" But, the methodology is unclear.</p><p>2.2 PN</p><p>The end of Introduction section says, "" a pro-spective, randomized, double-blind, placebo-controlledclinical trial"" But, the methodology is unclear.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>All patients enrolled in this study seemed to be analyzed.</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcome data for all patients are shown in Table 2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 PN</p><p>These extracted outcomes are objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes pre-registerd in the protocol were reported</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","18::overall","CD014937_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.808714813372781,-0.0246835809313562,-1.36373707980369,-0.253692546941873,-0.0506549699752209,0.00128780811250861,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Beaver 2018",2018,0,0,0,0,0,14,0,0,0,15,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed by the investigational drug services and concealed until the study was completed. (line 3, paragraph5, page 2)</p><p>1.2 Y</p><p>Random allocation sequences were generated by two-factor randomized block design stratified by gender.(line 1, paragraph 5, page 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.2 N</p><p>double-blinded, placebo-controlled, randomized clinical trial (line 5, paragraph 2, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes were pre-specified in the protocol</p><p>5.3 NI</p><p>Anayses were not desribed in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Ejaz 2009",2009,0,0.937191697424601,0,0,2,45,0,0,3,49,0,0.878328277721604,9.424926,0.725926,0.127055,4.147566,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.2 Y</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>1.3 N</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>Some concerns</p><p>2.1 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.2 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams<br>were blinded to group assignment.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>This study was not classified as ITT</p><p>2.7 PN</p><p>The influence might be minimal.</p>","Low risk","<p>3.1 PY</p><p>Outcomes of all patients were analyzed (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 N</p><p>The manuscript says, ""Random allocation sequences were generated by block stratification by the institutional investigational drug services and concealed until the study was completed. The study participants, physicians, nurses, and data analysis teams were blinded to group assignment.""</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>Predefined outcomes in the protocol were reported (line 1, paragraph 3, page 2)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Hisatomi 2012",2012,0,1.64685369190045,0,0,0,44,0,0,1,44,0,2.71212708252615,2.841985,0.333333,0.013948,7.966233,NA,"Low risk","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","High risk","<p>2.1 Y</p><p>open-label (line1, paragraph4, page 2)</p><p>2.2 Y</p><p>open-label (line1, paragraph4, page 2)</p><p>2.3 PY</p><p>The three dropouts from the Carperitide group were for the following reasons: (1) the surgical technique was changed to off-pump coronary artery bypass (OPCAB); (2) the start of carperitide treatment was too late; and (3) the patient was switched to another clinical trial. The three dropouts from the control group were for the following reasons: (1) the surgical technique was changed to OPCAB; (2) suffi cient data could not be obtained; and (3) the patient withdrew consent. (line 6, paragraph 6, page 2)</p><p>2.4 NI</p><p>It is unclear whether the deviations can affect outcomes. But 7 patients in Control group were administered carperitide because of heart failure and water balance problems after surgery (line 17, paragraph 6, page 3). The deviation favours the Control group.</p><p>2.5 N</p><p>11 excluded patients in Control group, 1 excluded patient in Carperitide group (Fig.1)</p><p>2.6</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Nearly 95% of outcome data were obtained.(Fig.2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 Y</p><p>open-label</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol is not available</p><p>5.3 NI</p><p>The protocol is not available</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Mori 2014",2014,0,1.53492675716571,0,0,0,20,0,0,0,22,0,2.35600014986325,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 Y</p><p>""Study protocol"" section says, "" A computerised random number generator was used to perform the allocation sequence."" and ""The random allocationsequences were concealed until the study had been com-pleted. ""</p><p>1.2 Y</p><p>""Study protocol"" section says, "" A computerised random number generator was used to perform the allocation sequence."" and ""The random allocationsequences were concealed until the study had been com-pleted. ""</p><p>1.3 PY</p><p>There might be a difference of the number of patients with diabetes mellitus betwee two groups</p>","High risk","<p>2.1 N</p><p>This study is a doule-blinded one. Also, ""Study protocol"" section says, "" The allocation into the treat-ment or the placebo group and the preparation of thestudy drug were performed by the hospital pharmacy.""</p><p>2.2 N</p><p>This study is a doule-blinded one. Also, ""Study protocol"" section says, "" The allocation into the treat-ment or the placebo group and the preparation of thestudy drug were performed by the hospital pharmacy.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows this study is not an ITT.</p><p>2.7 PY</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows the proportion of the lost follow-up is more than 10%.</p>","High risk","<p>3.1 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows some patients were lost or removed.</p><p>3.2 N</p><p>There seems to be no evidence of demonstrating the unbiasness</p><p>3.3 PY</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows the proportion of the lost follow-up is more than 10%.</p><p>3.4 NI</p><p>There is no information to demonstrate or deny the influence.</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 N</p><p>These extracted outcomes are objective.</p><p>4.3 N</p><p>Study protocol section says, "" The study participants, physicians, nurses and dataanalysis teams were blinded to group assignment.""</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>The prespecified protocol described the intended outcomes (UMIN000011650).</p><p>5.3 NI</p><p>The prespecified protocol does not describe the analysis plan (UMIN000011650).</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Sezai 2006a",2006,0,1.64125098727389,0,0,0,75,0,0,1,73,0,2.69370480322753,2.822852,0.324561,0.013436,7.840332,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Methods section, line7 says, ""The allocation was random"". But, the actual method was not mentioned in detail.</p><p>1.3 PN</p><p>There seems not to be much difference between the two groups in Table1.</p>","Some concerns","<p>2.1 NI</p><p>Althoug blind injection was performed in each group, blindeness for whom is unclear.</p><p>2.2 NI</p><p>Althoug blind injection was performed in each group, blindeness for whom is unclear.</p><p>2.3 PN</p><p>""blind injection"" might lead to no deviations</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>The data of two patients were not reported. The reason for the lost follow-up seems unclear.</p><p>2.7 PN</p><p>The number of deviation is small.</p>","High risk","<p>3.1 NI</p><p>148 of the 150 patients completed the protocol, but it is unclear wheter all patients were followed-up.</p><p>3.2 PN</p><p>148 of the 150 patients completed the protocol, but it is unclear wheter all patients were followed-up.</p><p>3.3 NI</p><p>There dose not seem to be any analysis about the missing.</p><p>3.4 NI</p><p>There dose not seem to be any analysis about the missing.</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 N</p><p>These extracted outcomes are objective.</p><p>4.3 NI</p><p>There is no information for the judgement.</p><p>4.4 N</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p><p>5.3 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Sezai 2007",2007,0,1.55966494933532,0,0,0,63,0,0,2,61,0,2.43255475418514,3.146766,0.19375,0.009491,3.955167,NA,"Some concerns","<p>1.1 NI</p><p>Method section, line8 says, ”We randomly assigned the patients into 2 groups as follow""</p><p>1.2 NI</p><p>Method section, line8 says, ”We randomly assigned the patients into 2 groups as follow""</p><p>1.3 PN</p><p>There seems not to be much difference between the two groups in Table1.</p>","High risk","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 NI</p><p>There is no information for the judgemen about the deviation.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>There is no information for the judgement about ITT analysis or study flow.</p><p>2.7 NI</p><p>There is no information for the judgement about ITT analysis or study flow.</p>","High risk","<p>3.1 NI</p><p>There is no information of the paricipants number in each table.</p><p>3.2 PN</p><p>It is not easy to demonstrate the unbiased result.</p><p>3.3 NI</p><p>There is no information for the judgement.</p><p>3.4 NI</p><p>There is no information for the judgement.</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 N</p><p>These extracted outcomes are objective.</p><p>4.3 NI</p><p>There is no information for the outcome assesor.</p><p>4.4 N</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>There is no enough information about the preregisterd protcol.</p><p>5.2 NI</p><p>There is no enough information about the preregisterd protcol or the intended outcomes.</p><p>5.3 NI</p><p>There is no enough information about the preregisterd protcol or the intended analysis.</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Sezai 2009",2009,0,1.49338755231033,0,0,0,251,0,0,4,253,0,2.23020638139544,3.365515,0.111993,0.006061,2.069322,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>The patients were randomly allocated to 2 groups bydrawing lots: 1 group received infusion of hANP in a blinded manner (hANP group) and 1 groupreceived physiological saline in the same manner (placebogroup).</p><p>2.2 N</p><p>The patients were randomly allocated to 2 groups bydrawing lots: 1 group received infusion of hANP in a blinded manner (hANP group) and 1 groupreceived physiological saline in the same manner (placebogroup).</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis automatically seemed to be applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcomes of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Sezai 2011a",2011,0,0,0,0,0,33,0,0,0,34,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1</p><p>1.2 NI</p><p>Study Protocol, line1</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind</p><p>2.2 N</p><p>double-blind</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>The number of exclusion was small.</p>","Low risk","<p>3.1 Y</p><p>There were only 3 deviations out of 68 subjects in the study (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PY</p><p>The primary outcome was different from the protocol.</p><p>5.3 NI</p><p>The detailed analysis plan was not mentioned in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Sezai 2011b",2011,0,0.76925347533414,0,0,2,141,0,0,13,144,0,0.591750909313653,13.239468,0.157119,0.036109,0.683676,NA,"Some concerns","<p>1.1 Y</p><p>They were randomized by the lottery method into 2 groups (page 2, paragraph 3, line 9)</p><p>1.2 NI</p><p>not reoprted</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>randomized, double-blind, placebo-controlled study (page 2, paragraph 3, line 2)</p><p>2.2 N</p><p>randomized, double-blind, placebo-controlled study (page 2, paragraph 3, line 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Per-protocol analyses was applied</p><p>2.7 PN</p><p>The number of exclusion was small.</p>","Low risk","<p>3.1 PY</p><p>None of them was lost to follow-up (page 3, pargraph 6, line 9)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data</p><p>4.2 N</p><p>The outcomes were objective including laboratory data</p><p>4.3 NI</p><p>not repoted</p><p>4.4 PN</p><p>The outcomes were objective including laboratory data</p><p>4.5</p>","High risk","<p>5.1</p><p>5.2 PY</p><p>Not all of prespecified outcomes were reported (e.g. renin activity)</p><p>5.3 NI</p><p>Detailed analysis plan was not provided in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Smith 2008",2008,0,0,0,0,0,23,0,0,0,24,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Some concerns","<p>2.1 NI</p><p>not reported</p><p>2.2 Y</p><p>Perfusionists caring for the patientin theatre were not blinded to group allocation,</p><p>2.3 PN</p><p>Only 1 in mannitol group and 2 in control group deviated from the protocol. (page 2, paragraph 5, line 2)</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>Only 1 in mannitol group and 2 in control group deviated from the protocol. (page 2, paragraph 5, line 2)</p>","Low risk","<p>3.1 PY</p><p>Nearly 95% of outcome data were obtained.(page 2, paragraph 5, line 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data</p><p>4.2 N</p><p>The outcomes were objective including laboratory data</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Sward 2004",2004,0,0.586577785945567,0,0,6,29,0,0,14,30,0,0.344073498964803,43.765294,0.44335,0.197469,0.995391,NA,"Low risk","<p>1.1 Y</p><p>A statistician using a computerized ran-dom-number generator performed the alloca-tion sequence. (page 2, paragraph 3, line 1)</p><p>1.2 Y</p><p>Treatment was assigned using closed envelopes. (page 2, paragraph 3, line 3)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind, placebo-controlled study (page 2, pargraph 2, line 2)</p><p>2.2 N</p><p>double-blind, placebo-controlled study (page 2, pargraph 2, line 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>The impact could be limited because the number of exclusion was small</p>","Low risk","<p>3.1 PY</p><p>Outcome data for all patients are reported in Table5.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.2 N</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.3 NI</p><p>not repoted</p><p>4.4 PN</p><p>The need for dialysis was determined according to the defined criteria</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Tholen 2023",2023,0,0.724620008328608,0,0,3,34,0,0,8,37,0,0.525074156470152,18.542966,0.408088,0.117797,1.413756,NA,"Low risk","<p>1.1 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.2 Y</p><p>a dedicated anesthetist nurse, not involved in the patient care, randomized the patients<br>to receive treatment with either ANP or placebo (saline) (1:1 allocation) by a web-based computerized random-number generator. (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.2 N</p><p>double-blind trial (page 2, paragraph 4, line 1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PN</p><p>per-protocol analysis seemed to be applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes we obtained were not pre-specified (protocol)</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Natriuretic peptide","SUBGROUP_AND_OVERALL","Witteles 2007",2007,0,1.64928837273758,0,0,0,39,0,0,1,36,0,2.72015213644738,2.850227,0.308333,0.012961,7.335004,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Randomization was performed by the research pharmacist at each site using a random number generator, but the detail is unclear.</p><p>1.3 PN</p><p>The proportion of coronary artery disease is significantly different. But the influence could not be substantial.</p>","Low risk","<p>2.1 PN</p><p>The end of Introduction section says, "" a pro-spective, randomized, double-blind, placebo-controlledclinical trial"" But, the methodology is unclear.</p><p>2.2 PN</p><p>The end of Introduction section says, "" a pro-spective, randomized, double-blind, placebo-controlledclinical trial"" But, the methodology is unclear.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>All patients enrolled in this study seemed to be analyzed.</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcome data for all patients are shown in Table 2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 PN</p><p>These extracted outcomes are objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes pre-registerd in the protocol were reported</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","Cinotti 2021",2021,0,0.664521833565957,0,0,6,82,0,0,4,89,0,0.441589267285862,27.279965,1.628049,0.476312,5.564718,NA,"Low risk","<p>1.1 Y</p><p>The randomization scheme was performed in blocks of 6, balanced (1:1 ratio) and stratified by center, chronic treatment by diuretic or not, and episode of acute kidney injury or not, defined as extra-renal replacement therapy or a creatinine blood level ≥180 μmol L−1 (page 3, paragraph 3, line 3)</p><p>1.2 Y</p><p>The randomization sequence was generated by a stat-istician at the clinical research unit (CHU Nantes) who had no role in patient recruitment. (page 3, paragraph 3, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.2 Y</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.3 PN</p><p>This study's intevention does not seem to deviate from clinical practice.</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>As planned, analyses were performed on all randomized patients meeting the study inclusion and non-inclusion criteria (Modified Intention to Treat Population)</p><p>2.7</p>","Low risk","<p>3.1 N</p><p>1 patient may lost to follow-up in Intervention group between Day 28 and 60 (Fig. 1)</p><p>3.2 PY</p><p>The number of missing data was small enough (only 1, Fig. 1)</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 PY</p><p>This study was single-blinded (page 3, paragraph 3, line 12)</p><p>4.4 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","Dussol 2006",2006,0,0,0,0,0,79,0,0,0,77,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.2 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 PN</p><p>Results of all patients were reported</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>Results of all patients were reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Results of all patients were reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1 NI</p><p>The protocol was not available</p><p>5.2 PN</p><p>The authors reported specific outcomes</p><p>5.3 NI</p><p>The number of pre-specified analyses was unclear</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","Fakhari 2017",2017,0,0,0,0,0,41,0,0,0,41,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.2 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.2 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p><p>2.7 PN</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p>","Low risk","<p>3.1 PY</p><p>Table2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 NI</p><p>The description about the outcome assessor was not available</p><p>4.4 PN</p><p>The outcome is objective</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The protocol was preregistered in IRCT138706091127N1.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","Hu 2021",2021,0,0,0,0,0,115,0,0,0,115,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.2 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.3 PN</p><p>The number of deviations in each group was small enough and almost the same.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>Not reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Only 1 in Intervention group, 2 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","Mahesh 2008",2008,0,1.66191419224295,0,0,1,21,0,0,0,21,0,2.76195878237852,4.164776,3,0.129126,69.699364,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>Double blinded-trial (page 2, paragraph 4, line 1)</p><p>2.2 N</p><p>Double blinded-trial (page 2, paragraph 4, line 1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported</p><p>2.7</p>","High risk","<p>3.1 NI</p><p>It was unclear whether all patients were followed up.</p><p>3.2 PN</p><p>There was no sensitivity analysis to correct the bias</p><p>3.3 NI</p><p>not reported</p><p>3.4 NI</p><p>not reported</p><p>&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.2 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>That is unclear becaus the protocol is not available</p><p>5.3 NI</p><p>That is unclear becaus the protocol is not available</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","Majumdar 2009",2009,0,0.705832676851931,0,0,5,46,0,0,4,46,0,0.498199767711963,26.388387,1.25,0.358255,4.361422,NA,"Low risk","<p>1.1 Y</p><p>Randomization was conducted by an independentbiostatistician at the Epidemiology Coordinating Centre</p><p>1.2 Y</p><p>we began to test this hypothesis in a randomized alloca-tion-concealed controlled trial with blinded ascer-tainment of outcomes (page 2, paragraph 4, line 7)</p><p>1.3 PN</p><p>The proportion of women was significantly higher in control group (Table 1).</p>","Some concerns","<p>2.1 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.2 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Only per-protocol analysis was applied</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""440895360050513138"" type=""FIGURE"">Figure 2</a>)</p>","Low risk","<p>3.1 N</p><p>5 in Intervention group and 6 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2 N</p><p>Only per-protocol analysis was applied</p><p>3.3 PN</p><p>Main cause of missing was ""Unable to contact"" and the proportion in each group was the same (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","PROTECT-TAVI 2015",2015,0,0,0,0,0,56,0,0,0,56,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was obtained with computer-generated codes, which were sealed in sequentiallynumbered envelopes</p><p>1.2 Y</p><p>Randomization was obtained with computer-generated codes, which were sealed in sequentiallynumbered envelopes</p><p>1.3 PN</p><p>Baseline characterics on Table 1 were almost the same between two groups and all p values were higher than 0.05</p>","Low risk","<p>2.1 NI</p><p>Not mentioned</p><p>2.2 NI</p><p>Not mentioned. Considering the method to apply RenalGuard system it was impossible to conceal which intervention was applied to each patient</p><p>2.3 PN</p><p>Results from all patients were reported</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>All analyses were performed following the intention-to-treat principle</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results from all patients were reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>AKI was defined as an absolute reduction in kidneyfunction (#72 h) and defined as: 1) stage 1: increase inserum creatinine to 150% to 200% (1.5 to 2.0 in-crease compared with baseline) or increase of 0.3mg/dl ($26.4 mmol/l); 2) stage 2: increase in serumcreatinine to 200% to 300% (2.0 to 3.0 increasecompared with baseline); and 3) stage 3: increase inserum creatinine to 300% (&gt;3 increase comparedwith baseline) or serum creatinine of 4.0 mg/dl(354 mmol/l) with an acute increase of at least 0.5mg/dl (44 mmol/l)</p><p>4.2 N</p><p>AKI was defined as an absolute reduction in kidneyfunction (#72 h) and defined as: 1) stage 1: increase inserum creatinine to 150% to 200% (1.5 to 2.0 in-crease compared with baseline) or increase of 0.3mg/dl ($26.4 mmol/l); 2) stage 2: increase in serumcreatinine to 200% to 300% (2.0 to 3.0 increasecompared with baseline); and 3) stage 3: increase inserum creatinine to 300% (&gt;3 increase comparedwith baseline) or serum creatinine of 4.0 mg/dl(354 mmol/l) with an acute increase of at least 0.5mg/dl (44 mmol/l)</p><p>4.3 NI</p><p>Not mentioned</p><p>4.4 N</p><p>All outcomes were objective and they could not be influenced by assessors</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","REDUCE-AKI 2019",2019,0,1.52170299383053,0,0,0,68,0,0,3,68,0,2.31558000143279,4.753541,0.142857,0.00752,2.714014,NA,"Low risk","<p>1.1 Y</p><p>patients were randomizedin a 1:1 fashion using closed envelopes by block randomization (groups of 10) (page 2, paragraph 9, line 2)</p><p>1.2 Y</p><p>patients were randomizedin a 1:1 fashion using closed envelopes by block randomization (groups of 10) (page 2, paragraph 9, line 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind, sham-controlled study (page 2, paragraph 3, lne 2)</p><p>2.2 N</p><p>double-blind, sham-controlled study (page 2, paragraph 3, lne 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>No deviation was reported (Table 2-6) and ITT analysis seemed to be automaticlly applied</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Table 2-6</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors' protocol paper says, ""Theinterventional cardiologist conducting the TAVI procedureis also blinded to the study treatment arm. The supervisingphysician, core labs, the biostatisticians performing the ana-lysis, the members of the Clinical Event Committee (CEC),aswellasthemembersoftheDataSafetyMonitoringBoard(DSMB)areblindedtotreatmentassignmentuntilstudy completion and after the database has been unlocked""</p><p>4.4</p><p>4.5</p>","Low risk","<p>5.1 Y</p><p>The analysis was performed based on the prespecified protocol</p><p>5.2 N</p><p>The pre-registerd protocol is available and outcome to be included in our analysis were pre-specified.</p><p>5.3 N</p><p>The pre-registerd protocol is available and analyses were pre-specified.</p>","Low risk","<p>'Low risk of bias' in all domains</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","REMEDIAL III 2020",2020,0,0.649921159754068,0,0,4,355,0,0,6,353,0,0.422397513896073,26.099785,0.662911,0.188688,2.328979,NA,"Low risk","<p>1.1 Y</p><p>An independent statistician generatedthe randomization list with permuted blocks, and theblock size was not disclosed to the investigatorsenrolling the patients (Random Allocation Software1.0, Microsoft Corp., Redmond, Washington) (page 4, paragraph 1, line 2).</p><p>1.2 Y</p><p>An independent statistician generatedthe randomization list with permuted blocks, and theblock size was not disclosed to the investigatorsenrolling the patients (Random Allocation Software1.0, Microsoft Corp., Redmond, Washington) (page 4, paragraph 1, line 2).</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiatedtrial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiatedtrial (page 2, paragraph 2, line 1)</p><p>2.3 Y</p><p>2 refused Foley cathether in UFR grouip (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.5</p><p>2.6 PN</p><p>Per-protocol analysis was applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 N</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 Y</p><p>""Patient population"" section, line 1 says, ""This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiated trial (6). ""</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Low risk","<p>5.1 PY</p><p>The analysis was performed based on the prespecified protocol</p><p>5.2 PN</p><p>Outcomes were pre-specified in the protocol</p><p>5.3 PN</p><p>All pre-specified analyses in the protocol were performed</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","STRENGTH 2022",2022,0,1.23139310495834,0,0,1,122,0,0,2,126,0,1.51632897893895,7.229391,0.516393,0.047435,5.621652,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Method says, ”Patients were randomized in a 1:1 ratio via an electronic data capture.” But there is no information about the process of clarifying the randmization.</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Some concerns","<p>2.1 Y</p><p>Their protocol (NCT02793661) says that this study is an open-label.</p><p>2.2 Y</p><p>Their protocol (NCT02793661) says that this study is an open-label.</p><p>2.3 NI</p><p>There is no information to demonstrate the deviation.</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>Figure1 shows that this study a kind of mITT.</p><p>2.7</p>","High risk","<p>3.1 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows some of the pariticipants were lost.</p><p>3.2 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows 218 of 248 patients were lost.</p><p>3.3 NI</p><p>There is no information to demonstrate or deny the influence.</p><p>3.4 NI</p><p>There is no information to demonstrate or deny the influence.</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>Their protocol (NCT02793661) says that this study is an open-label. There is no information about the outcome assessor.</p><p>4.4 PN</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The prespecified outcomes seem to be available in published report and supplementary file.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide","SUBGROUP_AND_OVERALL","Voigtländer‑Buschmann 2023",2023,0,0,0,0,1,47,0,0,0,51,0,0,4.084155,3.25,0.135631,77.876852,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Some concerns","<p>2.1 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.3 NI</p><p>the reasons for the withdrawal of the consent were not reported</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Spironolactone","SUBGROUP_AND_OVERALL","Barba-Navarro 2017",2017,0,0.719569967990306,0,0,4,115,0,0,4,118,0,0.51778093883357,100,1.026087,0.262856,4.005435,NA,"Low risk","<p>1.1 Y</p><p>Page 2. ""Randomization"" paragraph says, ""Randomization was per-formed by the Epidat 3.1 program, and allocation was imple-mented by a clinical research coordinator who was not directlyinvolved with the study.""</p><p>1.2 PY</p><p>Page 2. ""Randomization"" paragraph says, ""Randomization was per-formed by the Epidat 3.1 program, and allocation was imple-mented by a clinical research coordinator who was not directlyinvolved with the study.""</p><p>1.3 PN</p><p>Page 3 ""Study participants"" paragraph, line 4 says, ""No other significant variables were foundbetween groups (Table 1). ""</p>","High risk","<p>2.1 PN</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>2.2 PN</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows that this is not an ITT analysis.</p><p>2.7 PY</p><p>15/248 was omitted. Thus the influence might not be minimal.</p>","Low risk","<p>3.1 PY</p><p>All of the Table data were based on the same participants number.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 PN</p><p>These extracted outcomes are objective.</p><p>4.3 N</p><p>Page 2. ""Randomization"" paragraph says, ""Participants, care providers, and re-searchers were blinded to the intervention."", although the process of maintaining the blindness is unclear.</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>The definition of AKI was AKIN in the protocol, NCT02417896.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Mannitol","SUBGROUP_AND_OVERALL","Emara 2022",2022,0,0,0,0,0,39,0,0,0,41,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>a computer-generated table of random numbers with four or six permuted blocks (page 2, paragraph 6, line 3).</p><p>1.2 Y</p><p>The group allocation was concealed in sequentially numbered,<br>sealed, and opaque envelopes.(page 2, paragraph 6, line 5)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Some concerns","<p>2.1 N</p><p>This is a triple-blinded randomized controlled study (page 6, paragrph 5, line 1)</p><p>2.2 N</p><p>This is a triple-blinded randomized controlled study (page 6, paragrph 5, line 1)</p><p>2.3&nbsp;</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PN</p><p>modified ITT was applied (Table 1)</p><p>2.7 PN</p><p>≤ 5% were lost to follow-up</p>","Low risk","<p>3.1 Y</p><p>Results of almost all patients were reported (Table 3)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 N</p><p>The outcome is objective.</p><p>4.4&nbsp;</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 N</p><p>Prespecified outcomes in the protocol were reported</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Mannitol","SUBGROUP_AND_OVERALL","MAHAL 2021",2021,0,0.821237262806521,0,0,4,25,0,0,3,26,0,0.674430641821946,44.604413,1.386667,0.344474,5.581972,NA,"Low risk","<p>1.1 Y</p><p>Block randomization was done with block size of 10. An inde-pendent statistician using computer-generated random number table performed sequence generation (in line 1, paragraph 4, page 2).</p><p>1.2 Y</p><p>Allocation concealment was done using sequentially numbered, opaque, sealed envelopes. (in line 4, paragraph4, page 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 Y</p><p>open-label study (page 2, paragraph 3, line 21)</p><p>2.2 Y</p><p>open-label study (page 2, paragraph 3, line 21)</p><p>2.3 PN</p><p>Results of all patients were reported (Fig.2)</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported (Fig.2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Fig.2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and mortality</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and mortality</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and mortality</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>All outcomes declared in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not declared in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Mannitol","SUBGROUP_AND_OVERALL","Majumdar 2009",2009,0,0.705832676851931,0,0,5,46,0,0,4,46,0,0.498199767711963,55.395587,1.25,0.358255,4.361422,NA,"Low risk","<p>1.1 Y</p><p>Randomization was conducted by an independentbiostatistician at the Epidemiology Coordinating Centre</p><p>1.2 Y</p><p>we began to test this hypothesis in a randomized alloca-tion-concealed controlled trial with blinded ascer-tainment of outcomes (page 2, paragraph 4, line 7)</p><p>1.3 PN</p><p>The proportion of women was significantly higher in control group (Table 1).</p>","Some concerns","<p>2.1 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.2 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Only per-protocol analysis was applied</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""440895360050513138"" type=""FIGURE"">Figure 2</a>)</p>","Low risk","<p>3.1 N</p><p>5 in Intervention group and 6 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2 N</p><p>Only per-protocol analysis was applied</p><p>3.3 PN</p><p>Main cause of missing was ""Unable to contact"" and the proportion in each group was the same (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Mannitol","SUBGROUP_AND_OVERALL","Ridgen 1984",1984,0,0,0,0,0,20,0,0,0,20,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>There is not enough information to judge.</p><p>1.2 NI</p><p>There is not enough information to judge.</p><p>1.3 NI</p><p>There is not enough information about the backgrounds.</p>","High risk","<p>2.1 NI</p><p>There is no enough information to judge.</p><p>2.2 NI</p><p>There is no enough information to judge.</p><p>2.3 NI</p><p>There is no enough information to judge.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>There is no evidence for denying the appropriateness.</p><p>2.7 NI</p><p>There is no evidence for denying the appropriateness.</p>","High risk","<p>3.1 NI</p><p>There is no enough information to judge.</p><p>3.2 PN</p><p>There is no evidence.</p><p>3.3 NI</p><p>There is no enough information to judge.</p><p>3.4 NI</p><p>There is no enough information to judge.</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p><p>5.3 NI</p><p>There is no information about whether the study protocol was fixed in advance.</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Mannitol","SUBGROUP_AND_OVERALL","Smith 2008",2008,0,0,0,0,0,23,0,0,0,24,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Some concerns","<p>2.1 NI</p><p>not reported</p><p>2.2 Y</p><p>Perfusionists caring for the patientin theatre were not blinded to group allocation,</p><p>2.3 PN</p><p>Only 1 in mannitol group and 2 in control group deviated from the protocol. (page 2, paragraph 5, line 2)</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>Only 1 in mannitol group and 2 in control group deviated from the protocol. (page 2, paragraph 5, line 2)</p>","Low risk","<p>3.1 PY</p><p>Nearly 95% of outcome data were obtained.(page 2, paragraph 5, line 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data</p><p>4.2 N</p><p>The outcomes were objective including laboratory data</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Mannitol","SUBGROUP_AND_OVERALL","Svenmarker 2024",2024,0,0,0,0,0,98,0,0,0,97,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>not reported (just written as ""simple random sampling""</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Low risk","<p>2.1 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.2 PN</p><p>Double-blinded trial (page 2, paragraph 3, line1)</p><p>2.3&nbsp;</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 Y</p><p>Only 5 were lost to follow-up (Figure 1)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.2 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Acetazolamide","SUBGROUP_AND_OVERALL","Afzal 2021",2021,0,0,0,0,0,65,0,0,0,65,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>1.2 Y</p><p>An online statistical computing web program (www. Sealedenvelope.com) was utilized to randomize the assignment of the patient (page 2, paragraph 7, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 Y</p><p>open-labeled clinical trial (page 2, paragraph 4, line 1)</p><p>2.2 Y</p><p>open-labeled clinical trial (page 2, paragraph 4, line 1)</p><p>2.3 N</p><p>No deviation was observed in each group (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>No deviation was observed in each group (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Table 3-5)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Low risk","<p>5.1</p><p>5.2 N</p><p>Outcomes included in our analyses were prespecified.</p><p>5.3 NI</p><p>The detail of statistical analysis was not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Thiazide","SUBGROUP_AND_OVERALL","Piardi 2021",2021,0,1.65683373915903,0,0,1,26,0,0,0,25,0,2.74509803921569,100,2.888889,0.123181,67.751506,NA,"Low risk","<p>1.1 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.2 Y</p><p>An external investigator using a web-based software generated randomized sequences, divided in two blocks, and the resulting spreadsheet was sent to the pharmacist responsible for medications—HCTZ 50 mg and placebo, both stored inside identical numbered vials—and who had no scientific involvement in the study (Spengler Pharmacy, Porto Alegre, Brazil)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.2 N</p><p>All investigators and patients were blinded to the treatment assignment</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>ITT analysis seemed to be applied because denominator of the fraction in table 3 were 26 and 25 (before lost to follow-up)</p><p>2.7</p>","Low risk","<p>3.1 PN</p><p>In total, 4 patients lost to follow-up (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.2 N</p><p>No sensitivity analysis was performed</p><p>3.3 PN</p><p>All reasons for missingness were discharges (<a href=""443915394164620066"" type=""FIGURE"">Figure 3</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>All outcomes that were declared in the protocol were reported</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The outcome is prespecified in the protocol.</p><p>5.3 NI</p><p>Statistical analyses were not pre-specified in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide without RenalGuard","SUBGROUP_AND_OVERALL","Cinotti 2021",2021,0,0.664521833565957,0,0,6,82,0,0,4,89,0,0.441589267285862,47.170136,1.628049,0.476312,5.564718,NA,"Low risk","<p>1.1 Y</p><p>The randomization scheme was performed in blocks of 6, balanced (1:1 ratio) and stratified by center, chronic treatment by diuretic or not, and episode of acute kidney injury or not, defined as extra-renal replacement therapy or a creatinine blood level ≥180 μmol L−1 (page 3, paragraph 3, line 3)</p><p>1.2 Y</p><p>The randomization sequence was generated by a stat-istician at the clinical research unit (CHU Nantes) who had no role in patient recruitment. (page 3, paragraph 3, line 1)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.2 Y</p><p>This was a pragmatic multicenter, single-blind, ran-domized-controlled study (page 2, paragraph 4, line 1)</p><p>2.3 PN</p><p>This study's intevention does not seem to deviate from clinical practice.</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>As planned, analyses were performed on all randomized patients meeting the study inclusion and non-inclusion criteria (Modified Intention to Treat Population)</p><p>2.7</p>","Low risk","<p>3.1 N</p><p>1 patient may lost to follow-up in Intervention group between Day 28 and 60 (Fig. 1)</p><p>3.2 PY</p><p>The number of missing data was small enough (only 1, Fig. 1)</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 PY</p><p>This study was single-blinded (page 3, paragraph 3, line 12)</p><p>4.4 PN</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide without RenalGuard","SUBGROUP_AND_OVERALL","Dussol 2006",2006,0,0,0,0,0,79,0,0,0,77,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.2 Y</p><p>Randomization was performed using a computer-generatedrandomization list known only to the research physicianof the Centre d’Investigation Clinique (S.M.).</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 PN</p><p>Results of all patients were reported</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>Results of all patients were reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Results of all patients were reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1 NI</p><p>The protocol was not available</p><p>5.2 PN</p><p>The authors reported specific outcomes</p><p>5.3 NI</p><p>The number of pre-specified analyses was unclear</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide without RenalGuard","SUBGROUP_AND_OVERALL","Fakhari 2017",2017,0,0,0,0,0,41,0,0,0,41,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.2 Y</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.2 PN</p><p>The manuscript says "" The patients were allocated into either the furosemide (n=41) or the placebo (n=41) group, according to a randomization list that was prepared, using online software at a 1:1 ratio. The list was coded (A or B) and preprinted in sealed envelope packets. All except one of the authors were blinded to the treatment solution for every patient during the study.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p><p>2.7 PN</p><p>The authors seemed to perform a Per protocol analysis. But the effect could be minimal because the number was only one.</p>","Low risk","<p>3.1 PY</p><p>Table2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective</p><p>4.2 N</p><p>The outcome is objective</p><p>4.3 NI</p><p>The description about the outcome assessor was not available</p><p>4.4 PN</p><p>The outcome is objective</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The protocol was preregistered in IRCT138706091127N1.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide without RenalGuard","SUBGROUP_AND_OVERALL","Hu 2021",2021,0,0,0,0,0,115,0,0,0,115,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.2 Y</p><p>the absence of double-blind research methods may have affected our results (page 6, paragraph 3, line 3)</p><p>2.3 PN</p><p>The number of deviations in each group was small enough and almost the same.</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>Not reported</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Only 1 in Intervention group, 2 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide without RenalGuard","SUBGROUP_AND_OVERALL","Mahesh 2008",2008,0,1.66191419224295,0,0,1,21,0,0,0,21,0,2.76195878237852,7.201367,3,0.129126,69.699364,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>Double blinded-trial (page 2, paragraph 4, line 1)</p><p>2.2 N</p><p>Double blinded-trial (page 2, paragraph 4, line 1)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported</p><p>2.7</p>","High risk","<p>3.1 NI</p><p>It was unclear whether all patients were followed up.</p><p>3.2 PN</p><p>There was no sensitivity analysis to correct the bias</p><p>3.3 NI</p><p>not reported</p><p>3.4 NI</p><p>not reported</p><p>&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.2 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data in Table 2, 3</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>That is unclear becaus the protocol is not available</p><p>5.3 NI</p><p>That is unclear becaus the protocol is not available</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide without RenalGuard","SUBGROUP_AND_OVERALL","Majumdar 2009",2009,0,0.705832676851931,0,0,5,46,0,0,4,46,0,0.498199767711963,45.628497,1.25,0.358255,4.361422,NA,"Low risk","<p>1.1 Y</p><p>Randomization was conducted by an independentbiostatistician at the Epidemiology Coordinating Centre</p><p>1.2 Y</p><p>we began to test this hypothesis in a randomized alloca-tion-concealed controlled trial with blinded ascer-tainment of outcomes (page 2, paragraph 4, line 7)</p><p>1.3 PN</p><p>The proportion of women was significantly higher in control group (Table 1).</p>","Some concerns","<p>2.1 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.2 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>Only per-protocol analysis was applied</p><p>2.7 PN</p><p>The number of deviation was quite small (<a href=""440895360050513138"" type=""FIGURE"">Figure 2</a>)</p>","Low risk","<p>3.1 N</p><p>5 in Intervention group and 6 in Control group were lost to follow-up (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.2 N</p><p>Only per-protocol analysis was applied</p><p>3.3 PN</p><p>Main cause of missing was ""Unable to contact"" and the proportion in each group was the same (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors say, ""Patients, investigators, per-sonnel collecting all study outcomes, and the study ana-lyst remained masked to allocation status at all times untilMarch 2008.""(Page3, para1, line11)</p><p>4.4</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide with RenalGuard","SUBGROUP_AND_OVERALL","PROTECT-TAVI 2015",2015,0,0,0,0,0,56,0,0,0,56,0,0,NA,NA,NA,NA,NA,"Low risk","<p>1.1 Y</p><p>Randomization was obtained with computer-generated codes, which were sealed in sequentiallynumbered envelopes</p><p>1.2 Y</p><p>Randomization was obtained with computer-generated codes, which were sealed in sequentiallynumbered envelopes</p><p>1.3 PN</p><p>Baseline characterics on Table 1 were almost the same between two groups and all p values were higher than 0.05</p>","Low risk","<p>2.1 NI</p><p>Not mentioned</p><p>2.2 NI</p><p>Not mentioned. Considering the method to apply RenalGuard system it was impossible to conceal which intervention was applied to each patient</p><p>2.3 PN</p><p>Results from all patients were reported</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>All analyses were performed following the intention-to-treat principle</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results from all patients were reported</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>AKI was defined as an absolute reduction in kidneyfunction (#72 h) and defined as: 1) stage 1: increase inserum creatinine to 150% to 200% (1.5 to 2.0 in-crease compared with baseline) or increase of 0.3mg/dl ($26.4 mmol/l); 2) stage 2: increase in serumcreatinine to 200% to 300% (2.0 to 3.0 increasecompared with baseline); and 3) stage 3: increase inserum creatinine to 300% (&gt;3 increase comparedwith baseline) or serum creatinine of 4.0 mg/dl(354 mmol/l) with an acute increase of at least 0.5mg/dl (44 mmol/l)</p><p>4.2 N</p><p>AKI was defined as an absolute reduction in kidneyfunction (#72 h) and defined as: 1) stage 1: increase inserum creatinine to 150% to 200% (1.5 to 2.0 in-crease compared with baseline) or increase of 0.3mg/dl ($26.4 mmol/l); 2) stage 2: increase in serumcreatinine to 200% to 300% (2.0 to 3.0 increasecompared with baseline); and 3) stage 3: increase inserum creatinine to 300% (&gt;3 increase comparedwith baseline) or serum creatinine of 4.0 mg/dl(354 mmol/l) with an acute increase of at least 0.5mg/dl (44 mmol/l)</p><p>4.3 NI</p><p>Not mentioned</p><p>4.4 N</p><p>All outcomes were objective and they could not be influenced by assessors</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide with RenalGuard","SUBGROUP_AND_OVERALL","REDUCE-AKI 2019",2019,0,1.52170299383053,0,0,0,68,0,0,3,68,0,2.31558000143279,11.273165,0.142857,0.00752,2.714014,NA,"Low risk","<p>1.1 Y</p><p>patients were randomizedin a 1:1 fashion using closed envelopes by block randomization (groups of 10) (page 2, paragraph 9, line 2)</p><p>1.2 Y</p><p>patients were randomizedin a 1:1 fashion using closed envelopes by block randomization (groups of 10) (page 2, paragraph 9, line 2)</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind, sham-controlled study (page 2, paragraph 3, lne 2)</p><p>2.2 N</p><p>double-blind, sham-controlled study (page 2, paragraph 3, lne 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>No deviation was reported (Table 2-6) and ITT analysis seemed to be automaticlly applied</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Table 2-6</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 N</p><p>The authors' protocol paper says, ""Theinterventional cardiologist conducting the TAVI procedureis also blinded to the study treatment arm. The supervisingphysician, core labs, the biostatisticians performing the ana-lysis, the members of the Clinical Event Committee (CEC),aswellasthemembersoftheDataSafetyMonitoringBoard(DSMB)areblindedtotreatmentassignmentuntilstudy completion and after the database has been unlocked""</p><p>4.4</p><p>4.5</p>","Low risk","<p>5.1 Y</p><p>The analysis was performed based on the prespecified protocol</p><p>5.2 N</p><p>The pre-registerd protocol is available and outcome to be included in our analysis were pre-specified.</p><p>5.3 N</p><p>The pre-registerd protocol is available and analyses were pre-specified.</p>","Low risk","<p>'Low risk of bias' in all domains</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide with RenalGuard","SUBGROUP_AND_OVERALL","REMEDIAL III 2020",2020,0,0.649921159754068,0,0,4,355,0,0,6,353,0,0.422397513896073,61.896422,0.662911,0.188688,2.328979,NA,"Low risk","<p>1.1 Y</p><p>An independent statistician generatedthe randomization list with permuted blocks, and theblock size was not disclosed to the investigatorsenrolling the patients (Random Allocation Software1.0, Microsoft Corp., Redmond, Washington) (page 4, paragraph 1, line 2).</p><p>1.2 Y</p><p>An independent statistician generatedthe randomization list with permuted blocks, and theblock size was not disclosed to the investigatorsenrolling the patients (Random Allocation Software1.0, Microsoft Corp., Redmond, Washington) (page 4, paragraph 1, line 2).</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiatedtrial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiatedtrial (page 2, paragraph 2, line 1)</p><p>2.3 Y</p><p>2 refused Foley cathether in UFR grouip (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.4 PN</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.5</p><p>2.6 PN</p><p>Per-protocol analysis was applied (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p><p>2.7 N</p><p>The number of deviation was quite small (<a href=""438659130991609896"" type=""FIGURE"">Figure 1</a>)</p>","Low risk","<p>3.1 PY</p><p>Over 95% of patients were followed up (page 4, paragraph 3, line 7)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 Y</p><p>""Patient population"" section, line 1 says, ""This is a multicenter, ran-domized, unblinded, phase 3, investigator-initiated trial (6). ""</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Low risk","<p>5.1 PY</p><p>The analysis was performed based on the prespecified protocol</p><p>5.2 PN</p><p>Outcomes were pre-specified in the protocol</p><p>5.3 PN</p><p>All pre-specified analyses in the protocol were performed</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide with RenalGuard","SUBGROUP_AND_OVERALL","STRENGTH 2022",2022,0,1.23139310495834,0,0,1,122,0,0,2,126,0,1.51632897893895,17.144717,0.516393,0.047435,5.621652,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Method says, ”Patients were randomized in a 1:1 ratio via an electronic data capture.” But there is no information about the process of clarifying the randmization.</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Some concerns","<p>2.1 Y</p><p>Their protocol (NCT02793661) says that this study is an open-label.</p><p>2.2 Y</p><p>Their protocol (NCT02793661) says that this study is an open-label.</p><p>2.3 NI</p><p>There is no information to demonstrate the deviation.</p><p>2.4</p><p>2.5</p><p>2.6 PY</p><p>Figure1 shows that this study a kind of mITT.</p><p>2.7</p>","High risk","<p>3.1 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows some of the pariticipants were lost.</p><p>3.2 N</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows 218 of 248 patients were lost.</p><p>3.3 NI</p><p>There is no information to demonstrate or deny the influence.</p><p>3.4 NI</p><p>There is no information to demonstrate or deny the influence.</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>Their protocol (NCT02793661) says that this study is an open-label. There is no information about the outcome assessor.</p><p>4.4 PN</p><p>These extracted outcomes are objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The prespecified outcomes seem to be available in published report and supplementary file.</p><p>5.3 NI</p><p>Detailed analyses plan was not described in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
1,21,"Subgroup analysis: any use of KRT by type of diuretic","Furosemide with RenalGuard","SUBGROUP_AND_OVERALL","Voigtländer‑Buschmann 2023",2023,0,0,0,0,1,47,0,0,0,51,0,0,9.685697,3.25,0.135631,77.876852,NA,"Some concerns","<p>1.1 NI</p><p>not reported</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)&nbsp;</p>","Some concerns","<p>2.1 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.2 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>2.3 NI</p><p>the reasons for the withdrawal of the consent were not reported</p><p>2.4&nbsp;</p><p>2.5&nbsp;</p><p>2.6 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>2.7&nbsp;</p>","Low risk","<p>3.1 PY</p><p>Results of almost all patients were reported (Table 3)</p><p>3.2&nbsp;</p><p>3.3&nbsp;</p><p>3.4&nbsp;</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 Y</p><p>open-label trial (page 2, paragraph 2, line 1)</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5&nbsp;</p>","Some concerns","<p>5.1&nbsp;</p><p>5.2 PN</p><p>All outcomes in the protocol were reported</p><p>5.3 NI</p><p>The detail of analyses were not reported in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","21::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.275724014286095,-0.00978375043840675,-0.600093466414589,0.0486454378423989,-0.0169108462637193,-0.0026566546130942,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","AQUAMARINE 2016",2016,0,0,0,0,4,108,0,0,5,109,0,0,0.889165,0.807407,0.222796,2.926029,NA,"Low risk","<p>1.1 Y</p><p>An automated web-based randomization systemcreated by a 3rd-party company (Mebix, Tokyo, Japan) was used.</p><p>1.2 Y</p><p>An automated web-based randomization systemcreated by a 3rd-party company (Mebix, Tokyo, Japan) was used.</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Some concerns","<p>2.1 Y</p><p>This study is open-label</p><p>2.2 Y</p><p>This study is open-label</p><p>2.3 PN</p><p>Only 2 patients in each group deviated (Fig.1)</p><p>2.4</p><p>2.5</p><p>2.6 N</p><p>not ITT analysis</p><p>2.7 PN</p><p>The impact could be limited because the number of exclusion was small.</p>","Low risk","<p>3.1 Y</p><p>Over 95% of outcomes in both group were obtained.(FIg. 1)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 Y</p><p>This study is open-label</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Low risk","<p>5.1 Y</p><p>The analysis was performed according to a pre-specified protocol</p><p>5.2 N</p><p>The outcome is prespecified in the protocol.</p><p>5.3 N</p><p>Detailed analyses were prespecified in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Abraham 2021",2021,0,0,0,0,3,38,0,0,3,37,0,0,0.625662,0.973684,0.209797,4.51894,NA,"Low risk","<p>1.1 Y</p><p>A web-based, computer-generated, unstratified block ran-domization (in line 1, paragraph 3, page 2)</p><p>1.2 Y</p><p>The random number allocation was performed by aperson not involved in the study. Individual assignments wereplaced in sequentially numbered, opaque sealed envelopes(SNOSE) in line 3, paragraph 3, page 2</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind, placebo-controlled, randomized pilot trial (line 1, paragraph 2, page 2)</p><p>2.2 N</p><p>double-blind, placebo-controlled, randomized pilot trial (line 1, paragraph 2, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes defined in the protocol were reported (Table 2)</p><p>5.3 NI</p><p>The anaysis plan was not described in the protocol</p>","Some concerns","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Allgren 1997",1997,0,0,0,0,73,243,0,0,67,255,0,2.05868623109068,18.639425,1.143357,0.863077,1.514657,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Not repored</p><p>1.3 PN</p><p>Baseline characteristics on Table 1 were not significantly different between two groups</p>","Low risk","<p>2.1 N</p><p>To enroll a patient, a member of the staff at the study site tele-phoned an independent Study Randomization and Interim Anal-ysis Center that randomly assigned eligible patients in a double-blind manner in a 1:1 ratio (line 1, paragraph 2, page 2</p><p>2.2 N</p><p>To enroll a patient, a member of the staff at the study site tele-phoned an independent Study Randomization and Interim Anal-ysis Center that randomly assigned eligible patients in a double-blind manner in a 1:1 ratio (line 1, paragraph 2, page 2</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>The final analysis was performed on an intention-to-treat basis (line 11, paragraph 7, page 2)</p><p>2.7</p>","Low risk","<p>3.1 N</p><p>One patient in the placebo group was lost to follow-up on day 11 without having undergone dialysis. (line 4, paragraph 8, page 2)</p><p>3.2 PY</p><p>One patient in the placebo group was lost to follow-up on day 11 without having undergone dialysis. (line 4, paragraph 8, page 2)</p><p>3.3 PN</p><p>The number of deviations was small enough</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including survival or dialysis free survival (Table 2)</p><p>4.2 N</p><p>The outcomes were objective including survival or dialysis free survival (Table 2)</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including survival or dialysis free survival (Table 2)</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>That is unclear becaus the protocol is not available</p><p>5.3 NI</p><p>That is unclear becaus the protocol is not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Cantarovich 1971",1971,0,0,0,0,15,34,0,0,7,13,0,0,3.718748,0.819328,0.436542,1.537763,NA,"Some concerns","<p>1.1</p><p>just described as ""assigned at random"" (page 1 , paragraph 5, line 7)</p><p>1.2 NI</p><p>not reported</p><p>1.3 NI</p><p>Only the information of aetiology of the cause of acute renal failure was provided (Table 1)</p>","Some concerns","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 NI</p><p>not reported</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>All outcomes of studied patietns were provided (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>All outcomes of studied patietns were provided (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.2 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including laboratory data and any use of KRT</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>not reported and the protocol was not available</p><p>5.3 NI</p><p>not reported and the protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Cantarovich 2004",2004,0,0,0,0,59,166,0,0,50,164,0,0,15.455998,1.165783,0.856044,1.587594,NA,"High risk","<p>1.1</p><p>1.2 NI</p><p>1.3 PY</p><p>Table 1 shows the difference in proportion of sepsis and serum creatinine values.</p>","Low risk","<p>2.1 N</p><p>randomized, double-blind, placebo-controlled, multicenter trial (page 2, paragraph 3, line 2)</p><p>2.2 N</p><p>randomized, double-blind, placebo-controlled, multicenter trial (page 2, paragraph 3, line 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported and ITT analysis was automatically applied (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcomes of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Hamishehkar 2017",2017,0,0,0,0,10,50,0,0,14,50,0,0,2.919713,0.714286,0.350982,1.453646,NA,"Low risk","<p>1.1 Y</p><p>Individuals were randomized into two groups using Internet‑based software</p><p>1.2 Y</p><p>Individuals were randomized into two groups using Internet‑based software</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Low risk","<p>2.1 N</p><p>Double blinded (protocol: IRCT201205092582N8)</p><p>2.2 N</p><p>Double blinded (protocol: IRCT201205092582N8)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>The results of all participants were reported (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcome data for all patients are shown in Table 2</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>All outcomes that were declared in the protocol were reported</p><p>5.3 NI</p><p>No statistical analysis plan were shared in the protocol (IRCT201205092582N8)</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Herbert 1999",1999,0,0,0,0,0,6,0,0,0,6,0,0,NA,NA,NA,NA,NA,"Some concerns","<p>1.1 NI</p><p>Any detailed method for randomization was decribed</p><p>1.2 NI</p><p>No description about concealment</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind (line 6 in Patients and methods section)</p><p>2.2 N</p><p>double-blind (line 6 in Patients and methods section)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Outcomes of all patients were reported (Table 1-4)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Outcomes of all patients were reported (Table 1-4)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol is not available</p><p>5.3 NI</p><p>The protocol is not available</p>","Some concerns","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Kleinknecht 1976",1976,0,0,0,0,13,33,0,0,12,33,0,0,3.850802,1.083333,0.583525,2.011244,NA,"Some concerns","<p>1.1 NI</p><p>just reported as ""all patients were allocated randomly"" (page 2, paragraph 4, line 1)</p><p>1.2 NI</p><p>not reported</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","High risk","<p>2.1 NI</p><p>not reported</p><p>2.2 NI</p><p>not reported</p><p>2.3 NI</p><p>not reported</p><p>2.4</p><p>2.5</p><p>2.6 NI</p><p>Whether there were some deviations or not was not reported</p><p>2.7 NI</p><p>Whether there were some deviations or not was not reported</p>","High risk","<p>3.1 NI</p><p>Whether there were some missing data or not was not reported</p><p>3.2 N</p><p>No sensitivity analysis was performed</p><p>3.3 NI</p><p>Whether there were some missing data or not was not reported</p><p>3.4 NI</p><p>Whether there were some missing data or not was not reported</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Lewis 2000",2000,0,0,0,0,65,108,0,0,64,114,0,0,29.567045,1.072049,0.857518,1.34025,NA,"Low risk","<p>1.1 NI</p><p>not reported</p><p>1.2 Y</p><p>To enroll a patient, a member of the staff at the individual study site telephoned an independent study randomization and interim analysis center that randomly assigned eligible patients</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Low risk","<p>2.1 PN</p><p>This was a randomized, double-blind, placebo-controlled, clini-cal trial.</p><p>2.2 PN</p><p>This was a randomized, double-blind, placebo-controlled, clini-cal trial.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>ITT analysis</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>No patients were lost to follow-up</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 PN</p><p>The need for dialysis was determined by eachpatient’s attending nephrologist on a case-by-case basis,with need judged on the basis of the presence of volume overload, electrolyte imbalance, uremia, or acid-based distur-bances not responsive to medical management.</p><p>4.2 PN</p><p>The need for dialysis was determined by eachpatient’s attending nephrologist on a case-by-case basis,with need judged on the basis of the presence of volume overload, electrolyte imbalance, uremia, or acid-based distur-bances not responsive to medical management.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The need for dialysis was determined by eachpatient’s attending nephrologist on a case-by-case basis,with need judged on the basis of the presence of volume overload, electrolyte imbalance, uremia, or acid-based distur-bances not responsive to medical management.</p><p>4.5</p>","Some concerns","<p>5.1 NI</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Meyer 1999",1999,0,0,0,0,51,114,0,0,24,58,0,0,10.882605,1.08114,0.748245,1.562142,NA,"Some concerns","<p>1.1 NI</p><p>There is not enough information to judge.</p><p>1.2 NI</p><p>There is not enough information to judge.</p><p>1.3 PN</p><p>There seems to be no critical problems.</p>","Low risk","<p>2.1 PN</p><p>Although the metholodogy is unclear, ""Study Design"" section says ""The present study was designed as a double-blind, randomized, placebo-controlled, parallel group, multicenter, dose-finding triial. ""</p><p>2.2 PN</p><p>Although the metholodogy is unclear, ""Study Design"" section says ""The present study was designed as a double-blind, randomized, placebo-controlled, parallel group, multicenter, dose-finding triial. ""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows that this is a modified ITT analysis.</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>all almost of patients data seemed to be reported.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective</p><p>4.5 N</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>There is not enough information to judge.</p><p>5.3 NI</p><p>There is not enough information to judge.</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Mitaka 2017",2017,0,0,0,0,2,37,0,0,3,40,0,0,0.491144,0.720721,0.127461,4.075277,NA,"Some concerns","<p>1.1 Y</p><p>the INDICE randomization system (line 3, paragraph 4, page 2)</p><p>1.2 NI</p><p>Any description about concealment was provided.</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind placebo-controlled study (line 2, paragraph 3, page 2)</p><p>2.2 N</p><p>double-blind placebo-controlled study (line 2, paragraph 3, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes defined in the protocol were reported (Table 3-4)</p><p>5.3 NI</p><p>The anaysis plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","SPARK 2010",2010,0,0,0,0,8,37,0,0,11,36,0,0,2.381896,0.707617,0.322214,1.554002,NA,"Some concerns","<p>1.1 Y</p><p>Page 2, ""2.2 Randomization and blinding paragraph"" says, ""Eligible participants were randomly allocated in a 1:1 ratio to furose-mide (bolus followed by continuous infusion) or placebo-control (0.9%saline). Computerized random blocks of variable size (4–8) were strat-ified within each site and by the presence of sepsis. Randomization wasperformed by an unblinded clinical trial pharmacist using a web-basedapplication through the Epidemiology Coordinating and Research Cen-tre (EPICORE) at the University of Alberta (available at:https://www.epicore.ualberta.ca/home/). This was concealed from studyinvestigators.""</p><p>1.2 Y</p><p>Page 2, ""2.2 Randomization and blinding paragraph"" says, ""Eligible participants were randomly allocated in a 1:1 ratio to furose-mide (bolus followed by continuous infusion) or placebo-control (0.9%saline). Computerized random blocks of variable size (4–8) were strat-ified within each site and by the presence of sepsis. Randomization wasperformed by an unblinded clinical trial pharmacist using a web-basedapplication through the Epidemiology Coordinating and Research Cen-tre (EPICORE) at the University of Alberta (available at:https://www.epicore.ualberta.ca/home/). This was concealed from studyinvestigators.""</p><p>1.3 PY</p><p>Page 3, ""Baseline characteristics"" says, ""Participants al-located to furosemide had more exposure to vancomycin (67.6% vs.38.9%,p= 0.01).""</p>","Low risk","<p>2.1 N</p><p>Page 2, ""2.3 Procedures"" paragraph2 says, ""To ensure blinding of investigators and treating clinicians,study infusion bags for furosemide and placebo appeared identical andwere identified by a 4-digit coded identifier.""</p><p>2.2 N</p><p>Page 2, ""2.3 Procedures"" paragraph2 says, ""To ensure blinding of investigators and treating clinicians,study infusion bags for furosemide and placebo appeared identical andwere identified by a 4-digit coded identifier.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Figure1 indicates this is a ITT analysis.</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Outcome data for all patients are shown in Table 3</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The reported outcomes seem to be based on the preregistered protocol.</p><p>5.3 NI</p><p>Detailed analysis plan was not provided in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","Shilliday 1997",1997,0,0,0,0,38,62,0,0,13,30,0,0,7.135714,1.414392,0.897797,2.228237,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>1.3 PN</p><p>There seems not to be much difference between the two groups in Table2.</p>","Low risk","<p>2.1 N</p><p>double-blind study</p><p>2.2 N</p><p>double-blind study</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Four excluded patients died before allocation or were originally ineligible (page 2, paragraph 10, line 12)</p><p>2.7</p>","High risk","<p>3.1 NI</p><p>Only percent were provided on all Tables</p><p>3.2 PN</p><p>The number of missingness was not reported</p><p>3.3 NI</p><p>not reported</p><p>3.4 NI</p><p>not reported</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>the protocol was not available</p><p>5.3 NI</p><p>the protocol was not available</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,2,"Death","","SUBGROUP_AND_OVERALL","van der Voort 2009",2009,0,0,0,0,13,36,0,0,11,35,0,0,3.442084,1.14899,0.597184,2.210673,NA,"High risk","<p>1.1</p><p>1.2 NI</p><p>There seems to be no descriptions about the allocation process, although the ""Material and methods design"" section says, ""the study is a single-centered double blinded placebo-controlled trial.""</p><p>1.3 PY</p><p>There is a significant difference in ""Age"".</p>","Low risk","<p>2.1 N</p><p>Although the process of keeping the blindness is unclear, the ""Material and methods design"" section says, ""the study is a single-centered double blinded placebo-controlled trial.""</p><p>2.2 N</p><p>Although the process of keeping the blindness is unclear, the ""Material and methods design"" section says, ""the study is a single-centered double blinded placebo-controlled trial.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>The research process has been described in detail. These descriotions indicate that the analysis was perfomred as intention to treat analysis.</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>All patients had a complete follow-up until hospital discharge and hospital survivors were checked for dialysis dependency 2 months or more after hospital discharge.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>These extracted outcomes are objective.</p><p>4.2 N</p><p>These extracted outcomes are objective.</p><p>4.3 NI</p><p>There is no information about the outcome assessor.</p><p>4.4 N</p><p>These extracted outcomes are objective.</p><p>4.5</p>","High risk","<p>5.1</p><p>5.2 Y</p><p>The pre-registerd protocol is available. The expected outcomes in the preregtistered protocol were different from those reported in the paper.</p><p>5.3 NI</p><p>Detailed analysis plan was not provided in the protocol</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","2::overall","CD014937_pub2_data","direction_and_significance",FALSE,FALSE,TRUE,0.00164432376149952,-0.0115180189059566,-0.177646783974059,0.180935431497058,-0.0195256062096775,-0.0035104316022356,TRUE,TRUE
2,6,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Abraham 2021",2021,0,0,0,0,0,38,0,0,2,37,0,0,0.174609,0.194872,0.00967,3.927108,NA,"Low risk","<p>1.1 Y</p><p>A web-based, computer-generated, unstratified block ran-domization (in line 1, paragraph 3, page 2)</p><p>1.2 Y</p><p>The random number allocation was performed by aperson not involved in the study. Individual assignments wereplaced in sequentially numbered, opaque sealed envelopes(SNOSE) in line 3, paragraph 3, page 2</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind, placebo-controlled, randomized pilot trial (line 1, paragraph 2, page 2)</p><p>2.2 N</p><p>double-blind, placebo-controlled, randomized pilot trial (line 1, paragraph 2, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes defined in the protocol were reported (Table 2)</p><p>5.3 NI</p><p>The anaysis plan was not described in the protocol</p>","Some concerns","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
2,6,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Allgren 1997",1997,0,0,0,0,107,243,0,0,121,255,0,0,31.225909,0.927967,0.766033,1.124132,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>Not repored</p><p>1.3 PN</p><p>Baseline characteristics on Table 1 were not significantly different between two groups</p>","Low risk","<p>2.1 N</p><p>To enroll a patient, a member of the staff at the study site tele-phoned an independent Study Randomization and Interim Anal-ysis Center that randomly assigned eligible patients in a double-blind manner in a 1:1 ratio (line 1, paragraph 2, page 2</p><p>2.2 N</p><p>To enroll a patient, a member of the staff at the study site tele-phoned an independent Study Randomization and Interim Anal-ysis Center that randomly assigned eligible patients in a double-blind manner in a 1:1 ratio (line 1, paragraph 2, page 2</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>The final analysis was performed on an intention-to-treat basis (line 11, paragraph 7, page 2)</p><p>2.7</p>","Low risk","<p>3.1 N</p><p>One patient in the placebo group was lost to follow-up on day 11 without having undergone dialysis. (line 4, paragraph 8, page 2)</p><p>3.2 PY</p><p>One patient in the placebo group was lost to follow-up on day 11 without having undergone dialysis. (line 4, paragraph 8, page 2)</p><p>3.3 PN</p><p>The number of deviations was small enough</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcomes were objective including survival or dialysis free survival (Table 2)</p><p>4.2 N</p><p>The outcomes were objective including survival or dialysis free survival (Table 2)</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcomes were objective including survival or dialysis free survival (Table 2)</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>That is unclear becaus the protocol is not available</p><p>5.3 NI</p><p>That is unclear becaus the protocol is not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
2,6,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Lewis 2000",2000,0,0,0,0,69,108,0,0,88,114,0,0,36.013963,0.827652,0.695905,0.98434,NA,"Low risk","<p>1.1 NI</p><p>not reported</p><p>1.2 Y</p><p>To enroll a patient, a member of the staff at the individual study site telephoned an independent study randomization and interim analysis center that randomly assigned eligible patients</p><p>1.3 PN</p><p>There were not significant differences in table 1.</p>","Low risk","<p>2.1 PN</p><p>This was a randomized, double-blind, placebo-controlled, clini-cal trial.</p><p>2.2 PN</p><p>This was a randomized, double-blind, placebo-controlled, clini-cal trial.</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>ITT analysis</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>No patients were lost to follow-up</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 PN</p><p>The need for dialysis was determined by eachpatient’s attending nephrologist on a case-by-case basis,with need judged on the basis of the presence of volume overload, electrolyte imbalance, uremia, or acid-based distur-bances not responsive to medical management.</p><p>4.2 PN</p><p>The need for dialysis was determined by eachpatient’s attending nephrologist on a case-by-case basis,with need judged on the basis of the presence of volume overload, electrolyte imbalance, uremia, or acid-based distur-bances not responsive to medical management.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The need for dialysis was determined by eachpatient’s attending nephrologist on a case-by-case basis,with need judged on the basis of the presence of volume overload, electrolyte imbalance, uremia, or acid-based distur-bances not responsive to medical management.</p><p>4.5</p>","Some concerns","<p>5.1 NI</p><p>5.2 NI</p><p>The protocol was not available</p><p>5.3 NI</p><p>The protocol was not available</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
2,6,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Meyer 1999",1999,0,0.457252705744018,0,0,83,114,0,0,37,58,0,0.209080036910226,24.678937,1.141299,0.912256,1.427849,NA,"Some concerns","<p>1.1 NI</p><p>There is not enough information to judge.</p><p>1.2 NI</p><p>There is not enough information to judge.</p><p>1.3 PN</p><p>There seems to be no critical problems.</p>","Low risk","<p>2.1 PN</p><p>Although the metholodogy is unclear, ""Study Design"" section says ""The present study was designed as a double-blind, randomized, placebo-controlled, parallel group, multicenter, dose-finding triial. ""</p><p>2.2 PN</p><p>Although the metholodogy is unclear, ""Study Design"" section says ""The present study was designed as a double-blind, randomized, placebo-controlled, parallel group, multicenter, dose-finding triial. ""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p><a href=""438659130991609896"" type=""FIGURE"">Figure 1</a> shows that this is a modified ITT analysis.</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>all almost of patients data seemed to be reported.</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 N</p><p>The outcome is objective</p><p>4.5 N</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>There is not enough information to judge.</p><p>5.3 NI</p><p>There is not enough information to judge.</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
2,6,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Mitaka 2017",2017,0,0,0,0,1,37,0,0,3,40,0,0,0.319573,0.36036,0.039194,3.31324,NA,"Some concerns","<p>1.1 Y</p><p>the INDICE randomization system (line 3, paragraph 4, page 2)</p><p>1.2 NI</p><p>Any description about concealment was provided.</p><p>1.3 PN</p><p>Differences between two groups were not significant (Table 1)</p>","Low risk","<p>2.1 N</p><p>double-blind placebo-controlled study (line 2, paragraph 3, page 2)</p><p>2.2 N</p><p>double-blind placebo-controlled study (line 2, paragraph 3, page 2)</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Results of all patients were reported (Table 2)</p><p>2.7</p>","Low risk","<p>3.1 Y</p><p>Results of all patients were reported (Table 2)</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>Outcomes defined in the protocol were reported (Table 3-4)</p><p>5.3 NI</p><p>The anaysis plan was not described in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
2,6,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","SPARK 2010",2010,0,0,0,0,10,37,0,0,10,36,0,0,2.760029,0.972973,0.461057,2.053273,NA,"Some concerns","<p>1.1 Y</p><p>Page 2, ""2.2 Randomization and blinding paragraph"" says, ""Eligible participants were randomly allocated in a 1:1 ratio to furose-mide (bolus followed by continuous infusion) or placebo-control (0.9%saline). Computerized random blocks of variable size (4–8) were strat-ified within each site and by the presence of sepsis. Randomization wasperformed by an unblinded clinical trial pharmacist using a web-basedapplication through the Epidemiology Coordinating and Research Cen-tre (EPICORE) at the University of Alberta (available at:https://www.epicore.ualberta.ca/home/). This was concealed from studyinvestigators.""</p><p>1.2 Y</p><p>Page 2, ""2.2 Randomization and blinding paragraph"" says, ""Eligible participants were randomly allocated in a 1:1 ratio to furose-mide (bolus followed by continuous infusion) or placebo-control (0.9%saline). Computerized random blocks of variable size (4–8) were strat-ified within each site and by the presence of sepsis. Randomization wasperformed by an unblinded clinical trial pharmacist using a web-basedapplication through the Epidemiology Coordinating and Research Cen-tre (EPICORE) at the University of Alberta (available at:https://www.epicore.ualberta.ca/home/). This was concealed from studyinvestigators.""</p><p>1.3 PY</p><p>Page 3, ""Baseline characteristics"" says, ""Participants al-located to furosemide had more exposure to vancomycin (67.6% vs.38.9%,p= 0.01).""</p>","Low risk","<p>2.1 N</p><p>Page 2, ""2.3 Procedures"" paragraph2 says, ""To ensure blinding of investigators and treating clinicians,study infusion bags for furosemide and placebo appeared identical andwere identified by a 4-digit coded identifier.""</p><p>2.2 N</p><p>Page 2, ""2.3 Procedures"" paragraph2 says, ""To ensure blinding of investigators and treating clinicians,study infusion bags for furosemide and placebo appeared identical andwere identified by a 4-digit coded identifier.""</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Figure1 indicates this is a ITT analysis.</p><p>2.7</p>","Low risk","<p>3.1 PY</p><p>Outcome data for all patients are shown in Table 3</p><p>3.2</p><p>3.3</p><p>3.4</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 PN</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 N</p><p>The reported outcomes seem to be based on the preregistered protocol.</p><p>5.3 NI</p><p>Detailed analysis plan was not provided in the protocol</p>","Some concerns","<p>No 'High risk of bias' but one or more 'Some concerns'&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
2,6,"Sensitivity analysis: any use of KRT (placebo-controlled studies)","","SUBGROUP_AND_OVERALL","Shilliday 1997",1997,0,0.460596311479979,0,0,21,62,0,0,12,30,0,0.212148962148962,4.826982,0.846774,0.483927,1.481684,NA,"Some concerns","<p>1.1</p><p>1.2 NI</p><p>1.3 PN</p><p>There seems not to be much difference between the two groups in Table2.</p>","Low risk","<p>2.1 N</p><p>double-blind study</p><p>2.2 N</p><p>double-blind study</p><p>2.3</p><p>2.4</p><p>2.5</p><p>2.6 Y</p><p>Four excluded patients died before allocation or were originally ineligible (page 2, paragraph 10, line 12)</p><p>2.7</p>","High risk","<p>3.1 NI</p><p>Only percent were provided on all Tables</p><p>3.2 PN</p><p>The number of missingness was not reported</p><p>3.3 NI</p><p>not reported</p><p>3.4 NI</p><p>not reported</p>","Low risk","<p>4.1 N</p><p>The outcome is objective.</p><p>4.2 N</p><p>The outcome is objective.</p><p>4.3 NI</p><p>not reported</p><p>4.4 PN</p><p>The outcome is objective.</p><p>4.5</p>","Some concerns","<p>5.1</p><p>5.2 NI</p><p>the protocol was not available</p><p>5.3 NI</p><p>the protocol was not available</p>","High risk","<p>One or more 'High risk of bias' in any domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014937.pub2/full","10.1002/14651858.CD014937.pub2","6::overall","CD014937_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.179099250314711,-0.0452616844953493,-0.489942942559652,0.131744441930231,-0.0864990569801373,-0.00402431201056133,TRUE,TRUE
